Biotech Industry Financials, Performance and Ratios
-
Industry Score
45.7 /100
Rank 60 out of 131 Industries -
Advance/Decline
48/235
-
No. of Companies283
-
Avg. Market Cap2,750
-
Price to Earning Ratio4.27
-
Price to Earning Growth Ratio0.36
-
Price to Book Ratio13.73
-
Return on Equity34.96
-
Return on Capital Employed-
-
Return on Assets4.40
-
Dividend yield 1 year %0.29 %
-
Net Profit Growth Annual YoY %-30.63 %
-
Net Profit Growth Qtr YoY %-52.84 %
-
Net Profit Growth Qtr QoQ %81.43 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
11,984.3
|
24.1
|
L
 -2.0%
H
24.1
24.6
|
L
 -0.2%
H
24.1
25.3
|
L
 6.7%
H
22
25.3
|
L
 8.3%
H
20.4
25.3
|
L
 99.8%
H
8.0
25.3
|
L
 71.6%
H
7.9
25.3
|
L
 -19.1%
H
7.9
37.5
|
L
H
7.9
37.6
|
| Nuvation Bio Inc (Class A) |
|
1,817.0
|
5.3
|
L
 -5.5%
H
5.3
5.6
|
L
 -11.8%
H
5.3
6.3
|
L
 -43.6%
H
5.3
9.4
|
L
 5.2%
H
3.9
9.8
|
L
 112%
H
1.5
9.8
|
L
 119.0%
H
1.0
9.8
|
L
 -48.6%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
2,684.9
|
21.7
|
L
 -5.6%
H
21.6
23.5
|
L
 -1.1%
H
21.6
23.8
|
L
 -6.0%
H
20.6
24.6
|
L
 16.7%
H
18.3
26.4
|
L
 61.1%
H
6.5
26.4
|
L
 -6.2%
H
6.5
26.4
|
L
 -37.2%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
127.2
|
2.7
|
L
 -2.9%
H
2.6
2.8
|
L
 -5.6%
H
2.6
2.9
|
L
 1.1%
H
2.4
3.1
|
L
 11.6%
H
2.0
3.1
|
L
 -10%
H
1.4
3.8
|
L
 -78.9%
H
1.2
13.5
|
L
 -85.1%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,167.4
|
3.9
|
L
 -2.3%
H
3.9
4.1
|
L
 -6.3%
H
3.9
4.9
|
L
 8.9%
H
3.3
4.9
|
L
 -32.4%
H
3.3
5.8
|
L
 16.1%
H
1.9
6.5
|
L
 -63.8%
H
1.9
11.4
|
L
 -91.7%
H
1.9
55.2
|
L
H
1.9
71.9
|
| Arcellx Inc |
|
3,940.1
|
68.1
|
L
 -0.5%
H
67
69.1
|
L
 -5.6%
H
66
72
|
L
 3.7%
H
60.4
76.5
|
L
 -21.4%
H
60.4
93.2
|
L
 8.3%
H
47.9
94.1
|
L
 100.8%
H
26.3
107.4
|
L
H
6.0
107.4
|
L
H
6.0
107.4
|
| Adma Biologics Inc |
|
3,886.5
|
16.3
|
L
 -1.5%
H
16.2
16.6
|
L
 -7.2%
H
16.2
17.8
|
L
 -15.3%
H
16.2
19.4
|
L
 4.7%
H
13.8
20.5
|
L
 0.9%
H
13.5
25.7
|
L
 345.0%
H
2.9
25.7
|
L
 622.6%
H
1.0
25.7
|
L
 170.4%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,824.3
|
18.5
|
L
 -3.8%
H
18.4
19.3
|
L
 3.5%
H
17.3
19.4
|
L
 10.8%
H
15.3
19.4
|
L
 8.1%
H
13.3
20.8
|
L
 140.3%
H
6.3
20.8
|
L
 97.6%
H
2.3
20.8
|
L
 -66.1%
H
2.3
67.3
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
1.6
|
0.9
|
L
 -5.2%
H
0.9
1.0
|
L
 -22.0%
H
0.8
1.8
|
L
 -17.9%
H
0.7
1.8
|
L
 -95.8%
H
0.7
19.3
|
L
 -100.0%
H
0.7
438581.3
|
L
 -100.0%
H
0.7
3453280000
|
L
 -100.0%
H
0.7
10000000000
|
L
H
0.7
10000000000
|
| Agenus Inc |
|
112.4
|
3.1
|
L
 -2.5%
H
3.1
3.2
|
L
 -7.7%
H
3.0
3.6
|
L
 -6.0%
H
3.0
4.9
|
L
 -25.1%
H
3.0
4.9
|
L
 -13.6%
H
1.4
7.3
|
L
 -94.0%
H
1.4
196
|
L
 -95.8%
H
1.4
196
|
L
 -95.0%
H
1.4
196
|
| Aeglea BioTherapeutics Inc |
|
134.2
|
33.1
|
L
 -0.7%
H
32.5
34.0
|
L
 -1.8%
H
31.5
35.1
|
L
 0.6%
H
28
35.1
|
L
 34.9%
H
21.1
35.3
|
L
 118.3%
H
13.9
35.3
|
L
 159.9%
H
2.7
35.3
|
L
 -80.9%
H
2.7
219.8
|
L
H
2.7
318.8
|
| Avalon GloboCare Corp |
|
3.4
|
0.8
|
L
H
0.8
0.8
|
L
 -26.4%
H
0.8
1.0
|
L
 -39.1%
H
0.8
1.4
|
L
 -63.0%
H
0.8
2.2
|
L
 -76.1%
H
0.8
11.7
|
L
 -75.7%
H
0.2
11.7
|
L
 -93.8%
H
0.2
16.5
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
326.1
|
5.4
|
L
 -2.2%
H
5.4
5.6
|
L
 14.1%
H
4.7
5.7
|
L
 2.1%
H
3.9
5.7
|
L
 3.6%
H
3.9
5.7
|
L
 7.8%
H
1.1
7.2
|
L
 -11.0%
H
1.1
12.0
|
L
 -51.2%
H
1.1
16.0
|
L
 7.3%
H
1.1
16.7
|
| Alector Inc |
|
208.5
|
1.9
|
L
 -2.1%
H
1.9
2.0
|
L
 4.4%
H
1.8
2
|
L
 31.7%
H
1.4
2
|
L
 27.3%
H
1.1
2
|
L
 9.8%
H
0.9
3.4
|
L
 -79.1%
H
0.9
9.9
|
L
 -88.9%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
325.9
|
1.5
|
L
 -5.2%
H
1.5
1.5
|
L
 -7.6%
H
1.5
1.8
|
L
 5.1%
H
1.3
1.9
|
L
 17.9%
H
1.0
1.9
|
L
 -24.9%
H
0.9
3.8
|
L
 -81.7%
H
0.9
8.4
|
L
 -96.1%
H
0.9
39.1
|
L
H
0.9
55
|
| Altimmune Inc |
|
534.2
|
5.1
|
L
 -17.2%
H
5.0
6.4
|
L
 21.0%
H
4.2
6.4
|
L
 32.6%
H
3.5
6.4
|
L
 23.7%
H
3.5
6.4
|
L
 -26.9%
H
2.9
7.7
|
L
 -61.3%
H
2.1
16.0
|
L
 -62.4%
H
2.1
24.6
|
L
 -98.9%
H
1.5
1050
|
| Alvotech |
|
1,648.4
|
5.3
|
L
 -0.4%
H
5.2
5.4
|
L
 6.7%
H
4.9
5.5
|
L
 0.6%
H
4.4
5.5
|
L
 -34.9%
H
4.3
8.2
|
L
 -59.5%
H
4.3
13.1
|
L
 -55.2%
H
4.3
18
|
L
H
4.3
18
|
L
H
4.3
18
|
| Kalaris Therapeutics Inc |
|
176.7
|
9.5
|
L
 -1.7%
H
8.8
9.7
|
L
 -3.7%
H
8.8
10.5
|
L
 2.1%
H
7.9
10.5
|
L
 94.4%
H
4.5
11.9
|
L
 -5.0%
H
2.1
12.9
|
L
 64.3%
H
0.4
12.9
|
L
 -75.0%
H
0.4
47
|
L
H
0.4
49.0
|
| Amgen |
|
184,278.9
|
342.2
|
L
 -2.6%
H
340
352.0
|
L
 3.4%
H
329.3
353.3
|
L
 2.8%
H
318.2
353.3
|
L
 17.5%
H
288
353.3
|
L
 21.0%
H
261.4
353.3
|
L
 34.9%
H
211.7
353.3
|
L
 36.3%
H
198.6
353.3
|
L
 127.4%
H
133.6
353.3
|
| AnaptysBio Inc |
|
1,313.8
|
47.5
|
L
 -4.6%
H
46.6
49.4
|
L
 2.7%
H
44.4
50
|
L
 -5.3%
H
42
52.5
|
L
 31.2%
H
30.3
52.5
|
L
 171.8%
H
12.2
52.5
|
L
 96.8%
H
12.2
52.5
|
L
 103.6%
H
12.2
52.5
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,785.6
|
79.5
|
L
 -1.2%
H
78.1
80.6
|
L
 -7.3%
H
78.1
87.0
|
L
 -3.5%
H
75.1
87.1
|
L
 -14.4%
H
75.1
95.6
|
L
 31.6%
H
54.1
99.5
|
L
 82.3%
H
36.5
99.5
|
L
 157.9%
H
22.3
99.5
|
L
 143.3%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
101.1
|
3.0
|
L
 -1.6%
H
3
3.1
|
L
 -2.6%
H
3.0
3.4
|
L
 -5.3%
H
3.0
3.6
|
L
 -30.0%
H
3.0
5.5
|
L
 9.0%
H
2.3
5.5
|
L
 -32.1%
H
2.1
6.5
|
L
 -21.9%
H
2.1
8.1
|
L
 16.5%
H
0.6
8.1
|
| AN2 Therapeutics Inc |
|
32.6
|
1.2
|
L
 -0.8%
H
1.2
1.2
|
L
 0.9%
H
1.1
1.3
|
L
 4.4%
H
1
1.4
|
L
 -11.9%
H
1
1.4
|
L
 -5.6%
H
1
1.6
|
L
 -90.5%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
6.9
|
1.6
|
L
 4.6%
H
1.5
1.6
|
L
 0.6%
H
1.4
1.7
|
L
 -32.2%
H
1.2
2.3
|
L
 -57.9%
H
1.2
3.9
|
L
 -98.8%
H
0.7
145.9
|
L
 -100.0%
H
0.7
28335
|
L
 -100.0%
H
0.7
204600
|
L
 -100.0%
H
0.7
2244000
|
| Aptevo Therapeutics Inc |
|
7.8
|
7.8
|
L
 -5.1%
H
7.8
8.3
|
L
 -20.2%
H
7.8
10.0
|
L
 -28.3%
H
7.7
10.7
|
L
 -71.0%
H
7.7
28.4
|
L
 -99.5%
H
7.7
1688.4
|
L
 -100.0%
H
7.7
1406592
|
L
 -100.0%
H
7.7
25324516.8
|
L
H
7.7
68020444.8
|
| AquaBounty Tech Inc |
|
3.8
|
1.0
|
L
 -3.0%
H
1.0
1.0
|
L
 1.0%
H
1.0
1.2
|
L
 -3.9%
H
0.9
1.2
|
L
 -33.8%
H
0.8
1.5
|
L
 24.1%
H
0.5
3.0
|
L
 -95.7%
H
0.5
23.6
|
L
 -99.5%
H
0.5
234.2
|
L
H
0.5
610
|
| Arvinas Inc |
|
830.4
|
12.9
|
L
 -5.1%
H
12.8
13.7
|
L
 7.5%
H
11.9
13.7
|
L
 6.3%
H
11
13.7
|
L
 34.0%
H
9.3
14.2
|
L
 -29%
H
5.9
20.4
|
L
 -59.3%
H
5.9
53.1
|
L
 -81.2%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
9,181.9
|
65.6
|
L
 -2.0%
H
65.5
67.5
|
L
 0.5%
H
65.2
71.2
|
L
 -6.5%
H
60.6
76.8
|
L
 66.1%
H
37.1
76.8
|
L
 223.9%
H
9.6
76.8
|
L
 95.1%
H
9.6
76.8
|
L
 -14.6%
H
9.6
93.7
|
L
 1701.6%
H
1.2
93.7
|
| LeonaBio Inc |
|
45.3
|
4.9
|
L
 -9.5%
H
4.8
5.4
|
L
 -21.9%
H
4.8
6.6
|
L
 -35.2%
H
4.8
7.8
|
L
 16.9%
H
3.7
8.4
|
L
 -7.3%
H
2.2
8.4
|
L
 -88.2%
H
2.2
44.1
|
L
 -97.6%
H
2.2
258.0
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
1,920.9
|
14.6
|
L
H
14.4
14.6
|
L
 -1.5%
H
14.4
15.2
|
L
 -10.3%
H
14.4
16.2
|
L
 18.6%
H
12.0
16.5
|
L
 76.4%
H
6.6
16.5
|
L
 55.5%
H
4.7
16.5
|
L
 -9.2%
H
4.1
34.0
|
L
 593.8%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
344.2
|
5.4
|
L
 -4.2%
H
5.3
5.7
|
L
 9.1%
H
5.0
5.9
|
L
 -7.7%
H
4.7
6.3
|
L
 -11.2%
H
4.7
6.7
|
L
 -32.2%
H
4.3
8.3
|
L
 -46.2%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
370.4
|
19.8
|
L
 -2.9%
H
19.7
20.7
|
L
 3.6%
H
18.2
20.7
|
L
 -5.2%
H
17.8
22
|
L
 6.3%
H
15.5
26
|
L
 -51.9%
H
13.7
61.1
|
L
 85.5%
H
1.4
61.1
|
L
 -88.3%
H
1.4
240.8
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
771.3
|
15.6
|
L
 -2.6%
H
15.4
16.3
|
L
 2.6%
H
14.6
17.1
|
L
 -4.9%
H
12.5
17.1
|
L
 53.5%
H
8.4
17.7
|
L
 -82.6%
H
6.6
100.1
|
L
 -98.1%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
435.1
|
4.9
|
L
 -3.6%
H
4.9
5.1
|
L
 -3.2%
H
4.9
5.4
|
L
 33.8%
H
3.5
5.4
|
L
 -42.6%
H
2.9
8.5
|
L
 -50.4%
H
2.9
14.0
|
L
 -53.9%
H
2.9
14.4
|
L
 -19.2%
H
2.9
31.5
|
L
 35.3%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
9,334.9
|
185.2
|
L
 -1.5%
H
184
189.0
|
L
 0.4%
H
183.7
191.5
|
L
 21.8%
H
148.1
191.5
|
L
 37.5%
H
123.5
191.5
|
L
 80.3%
H
87.0
191.5
|
L
 163.5%
H
53.7
191.5
|
L
 167.7%
H
19.4
191.5
|
L
 1834.9%
H
1.9
191.5
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1.1
|
L
 5%
H
0.9
1.1
|
L
 25%
H
0.8
1.1
|
L
 94.4%
H
0.5
1.1
|
L
 16.7%
H
0.5
1.1
|
L
 -39.0%
H
0.5
2.6
|
L
 -76.5%
H
0.5
5.1
|
L
 -93.4%
H
0.5
16.7
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
8.9
|
0.3
|
L
 -10.7%
H
0.3
0.3
|
L
 -3.9%
H
0.3
0.3
|
L
 -7.4%
H
0.3
0.3
|
L
 -68.4%
H
0.2
0.8
|
L
 -80.6%
H
0.2
1.7
|
L
 -97.5%
H
0.2
10.4
|
L
 -99.6%
H
0.2
84.2
|
L
 -99.9%
H
0.2
444
|
| Autolus Therapeutics PLC (ADR) |
|
385.9
|
1.5
|
L
 2.1%
H
1.4
1.5
|
L
 2.1%
H
1.4
1.6
|
L
 -13.2%
H
1.3
2.1
|
L
 -12.1%
H
1.2
2.1
|
L
 -35.8%
H
1.1
2.7
|
L
 -22.9%
H
1.1
7.5
|
L
 -82.1%
H
1.1
8.9
|
L
H
1.1
53.2
|
| BridgeBio Pharma Inc |
|
14,849.2
|
77.5
|
L
 -0.5%
H
75.8
78.4
|
L
 0.4%
H
75.8
81.3
|
L
 2.2%
H
71.0
81.3
|
L
 21.9%
H
60.2
81.3
|
L
 111.3%
H
28.3
81.3
|
L
 750.6%
H
8.5
81.3
|
L
 39.7%
H
5.0
81.3
|
L
H
5.0
81.3
|
| BioAtla Inc |
|
19.9
|
0.3
|
L
 -3.1%
H
0.3
0.3
|
L
 -3.1%
H
0.3
0.4
|
L
 -63.1%
H
0.3
0.8
|
L
 -56.3%
H
0.3
1.4
|
L
 -36.7%
H
0.2
1.4
|
L
 -91.6%
H
0.2
4.4
|
L
 -99.3%
H
0.2
76.6
|
L
H
0.2
76.6
|
| BioCardia Inc |
|
13.8
|
1.3
|
L
 -1.5%
H
1.3
1.3
|
L
H
1.3
1.4
|
L
 2.4%
H
1.2
1.4
|
L
 -0.8%
H
1.2
1.5
|
L
 -42.7%
H
1
3.2
|
L
 -96.4%
H
1
43.8
|
L
 -97.9%
H
1
82.2
|
L
 -99.0%
H
1
2073.6
|
| Biocryst Pharma Inc |
|
1,651.9
|
6.7
|
L
 -1.5%
H
6.6
6.8
|
L
 -0.2%
H
6.6
7.2
|
L
 -12.7%
H
6.5
8.1
|
L
 -8.9%
H
6.5
8.2
|
L
 -16.9%
H
6
11.3
|
L
 -37.1%
H
4.0
11.3
|
L
 -24.0%
H
4.0
20.0
|
L
 -4.9%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
29.1
|
4.7
|
L
 -4.3%
H
4.5
5.2
|
L
 7.1%
H
4.2
5.2
|
L
 -39.5%
H
4.1
12.1
|
L
 -65.1%
H
4.1
13.8
|
L
 -99.2%
H
4.1
982
|
L
 -100.0%
H
4.1
12033
|
L
 -99.9%
H
4.1
18526.5
|
L
 -100.0%
H
4.1
138373.2
|
| Black Diamond Therapeutics Inc |
|
146.4
|
2.6
|
L
 -0.8%
H
2.6
2.7
|
L
 7.1%
H
2.4
2.7
|
L
 -0.8%
H
2.4
2.9
|
L
 -34.9%
H
2.2
4.9
|
L
 4.9%
H
1.2
4.9
|
L
 -14.3%
H
1.2
7.7
|
L
 -89.2%
H
1.2
29.6
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,944.8
|
29.0
|
L
 -5.5%
H
28.4
31.0
|
L
 -6.3%
H
28.4
35.3
|
L
 3.7%
H
26.3
36.4
|
L
 8.6%
H
20.2
36.4
|
L
 12%
H
13.5
36.4
|
L
 -35.9%
H
13.5
50.7
|
L
 -68.5%
H
13.5
138.5
|
L
H
13
138.5
|
| Biogen |
|
25,648.0
|
174.8
|
L
 0.4%
H
170.9
175.1
|
L
 5.7%
H
165.3
176.1
|
L
 -1.3%
H
160.4
190.2
|
L
 16.2%
H
138
190.2
|
L
 17.5%
H
110.0
190.2
|
L
 -39.7%
H
110.0
319.8
|
L
 -34.1%
H
110.0
468.6
|
L
 -30.5%
H
110.0
468.6
|
| BioVie Inc |
|
9.3
|
1.2
|
L
 1.7%
H
1.2
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 1.7%
H
1.1
1.4
|
L
 -34.9%
H
1.1
1.9
|
L
 -93.1%
H
1.1
20.4
|
L
 -99.8%
H
1.1
1139
|
L
 -100.0%
H
1.1
4609.8
|
L
 -99.9%
H
1.1
5625
|
| Biomarin pharma Inc - Registered Shares |
|
10,889.0
|
56.7
|
L
 -0.3%
H
56
57.3
|
L
 0.7%
H
55.5
58.3
|
L
 -5.5%
H
54.1
61.9
|
L
 7.6%
H
50.8
63.9
|
L
 -8.3%
H
50.8
73.5
|
L
 -51.7%
H
50.8
117.5
|
L
 -31.9%
H
50.8
117.8
|
L
 -29.3%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
15.4
|
1.5
|
L
 -2.0%
H
1.5
1.6
|
L
 4.9%
H
1.4
1.8
|
L
 -0.7%
H
1.4
1.8
|
L
 -20.9%
H
1.4
2.0
|
L
 -74.1%
H
1.4
6.3
|
L
 -91.8%
H
0.1
20.2
|
L
 -98.6%
H
0.1
156.9
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
409.1
|
12.1
|
L
 -3.8%
H
12.0
12.5
|
L
 3.9%
H
11.6
13.1
|
L
 -7.8%
H
11.2
14.4
|
L
 -23.1%
H
9.9
16.7
|
L
 12.1%
H
9.7
17.2
|
L
 210.5%
H
1.9
17.2
|
L
 -82.4%
H
1.9
178.3
|
L
 -98.6%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
13.4
|
1.7
|
L
 -1.8%
H
1.6
1.7
|
L
 -0.6%
H
1.6
1.7
|
L
 2.5%
H
1.5
1.8
|
L
 -14.1%
H
1.5
2.1
|
L
 -95.4%
H
1.1
73.8
|
L
 -99.4%
H
1.1
645
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
36.7
|
1.7
|
L
 -5.1%
H
1.7
1.8
|
L
 -11.1%
H
1.7
2.0
|
L
 1.2%
H
1.5
2.1
|
L
 -26.3%
H
1.5
2.3
|
L
 354.1%
H
0.2
8.1
|
L
 -94.7%
H
0.2
34.1
|
L
 -96.7%
H
0.2
67.7
|
L
H
0.2
71.5
|
| Bicycle Therapeutics PLC (ADR) |
|
456.4
|
6.6
|
L
 -6.9%
H
6.6
7.2
|
L
 -1.4%
H
6.6
7.3
|
L
 -3.5%
H
6.3
7.3
|
L
 -19.0%
H
6.0
9.1
|
L
 -49.5%
H
6.0
13.6
|
L
 -76.5%
H
6.0
30.0
|
L
 -74.4%
H
6.0
62.1
|
L
H
6.0
62.1
|
| BioNTech SE (ADR) |
|
29,148.1
|
116.2
|
L
 -2.7%
H
114.6
117.7
|
L
 10.0%
H
105.6
124
|
L
 22.9%
H
94
124
|
L
 9.5%
H
91.1
124
|
L
 -3%
H
81.2
126.8
|
L
 -19.1%
H
76.5
147.7
|
L
 9.6%
H
76.5
464
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
274.4
|
2.9
|
L
 -5.6%
H
2.8
3.1
|
L
 30.1%
H
2.2
3.3
|
L
 30.1%
H
2
3.3
|
L
 2.2%
H
2
3.7
|
L
 23.9%
H
1.0
3.7
|
L
 -76.0%
H
1.0
26.4
|
L
 -77.0%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
18.0
|
1.3
|
L
 -75.6%
H
0.8
1.8
|
L
 -77.7%
H
0.8
6.0
|
L
 -79.9%
H
0.8
7.2
|
L
 -58.8%
H
0.8
7.2
|
L
 -53.9%
H
0.8
7.2
|
L
 -86.9%
H
0.8
10.5
|
L
 -99.7%
H
0.8
492.5
|
L
H
0.8
530.3
|
| Tvardi Therapeutics Inc |
|
38.1
|
4.1
|
L
 -5.8%
H
4.0
4.4
|
L
 -12.3%
H
4.0
4.9
|
L
 -1.9%
H
3.9
4.9
|
L
 -16.6%
H
3.7
5
|
L
 -75.0%
H
3.7
43.7
|
L
 -99.1%
H
3.7
449.6
|
L
 -99.4%
H
3.7
1067.3
|
L
 -98.9%
H
3.7
1067.3
|
| Crescent Biopharma Inc |
|
-
|
10.7
|
L
 -4.8%
H
10.7
11.8
|
L
 -23.3%
H
10.7
14.7
|
L
 -13.1%
H
10.6
14.7
|
L
 -17.5%
H
10.6
16.4
|
L
 -5.5%
H
7.6
21.4
|
L
 142.8%
H
2.8
21.4
|
L
 -23.6%
H
0.9
21.4
|
L
 -86.5%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
196.7
|
2.0
|
L
 -5.1%
H
2
2.1
|
L
 -6.9%
H
2
2.2
|
L
 -4.3%
H
1.9
2.5
|
L
 -23.4%
H
1.9
2.8
|
L
 -43.9%
H
1.1
3.8
|
L
 -74.1%
H
1.1
11.9
|
L
 -94.2%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
182.4
|
2.0
|
L
 -3.5%
H
1.9
2.0
|
L
 -10.6%
H
1.9
2.2
|
L
 26.6%
H
1.4
2.4
|
L
 14.0%
H
1.4
2.4
|
L
 -13.7%
H
1.1
2.7
|
L
 124.1%
H
0.5
3.0
|
L
 -83.0%
H
0.5
14.2
|
L
 -57.0%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
109.5
|
1.2
|
L
 -6.1%
H
1.2
1.3
|
L
 -11.4%
H
1.2
1.5
|
L
 -14.5%
H
1.2
1.6
|
L
 -26.2%
H
1.2
1.8
|
L
 74.7%
H
0.2
3.8
|
L
 -38.6%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coeptis Therapeutics Holdings Inc |
|
72.4
|
13.6
|
L
 2.0%
H
13.3
14.3
|
L
 9.7%
H
12.5
14.5
|
L
 -7.4%
H
11.3
16.0
|
L
 -9.8%
H
11.3
21.4
|
L
 5.3%
H
6.3
21.4
|
L
 -57.1%
H
2.3
43.8
|
L
 35.3%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,888.5
|
38.4
|
L
 -0.4%
H
37.8
39.1
|
L
 -3.9%
H
36.0
40.4
|
L
 -1.3%
H
32.9
41.4
|
L
 136.8%
H
13.8
43.7
|
L
 352.9%
H
3.7
43.7
|
L
 165.8%
H
3.7
43.7
|
L
 299.6%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Caribou Biosciences Inc |
|
142.1
|
1.5
|
L
 -1.9%
H
1.5
1.6
|
L
 9.4%
H
1.4
1.7
|
L
 -10.6%
H
1.4
1.8
|
L
 -38.0%
H
1.4
3.5
|
L
 2.7%
H
0.7
3.5
|
L
 -79.1%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
110.3
|
1.0
|
L
 -1%
H
1.0
1
|
L
 -2.0%
H
1.0
1.1
|
L
H
0.9
1.1
|
L
 -18.9%
H
0.9
1.2
|
L
 -23.3%
H
0.8
1.6
|
L
 41.4%
H
0.5
3.1
|
L
 -67.9%
H
0.5
5.3
|
L
H
0.5
8.5
|
| Curis Inc |
|
11.9
|
0.9
|
L
 -3.2%
H
0.9
1.0
|
L
 -5.2%
H
0.9
1.0
|
L
 -13.2%
H
0.8
1.1
|
L
 -41.0%
H
0.8
1.6
|
L
 -71.0%
H
0.8
3.6
|
L
 -94.1%
H
0.8
20
|
L
 -99.5%
H
0.8
348
|
L
 -99.5%
H
0.8
372
|
| CorMedix Inc |
|
610.6
|
7.8
|
L
H
7.7
7.9
|
L
 12.7%
H
6.8
7.9
|
L
 -38.2%
H
6.6
13.0
|
L
 -29.9%
H
6.6
13.0
|
L
 -37.4%
H
5.6
17.4
|
L
 79.8%
H
2.6
17.4
|
L
 -11.5%
H
2.6
18.8
|
L
 -12.9%
H
0.9
22.7
|
| CRISPR Therapeutics AG |
|
5,116.7
|
53.7
|
L
 -1.1%
H
53.1
54.6
|
L
 2.1%
H
51.8
60.9
|
L
 -2.5%
H
51
60.9
|
L
 -18.3%
H
48.0
66.0
|
L
 28.3%
H
30.0
78.5
|
L
 1.7%
H
30.0
91.1
|
L
 -67.3%
H
30.0
175.4
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
105.8
|
7.6
|
L
 -0.9%
H
7.4
7.7
|
L
 8.9%
H
6.6
7.7
|
L
 9.2%
H
6.5
7.7
|
L
 11.7%
H
6.0
8.3
|
L
 -34.9%
H
5.6
12.0
|
L
 85.4%
H
3.6
12.0
|
L
 -33.0%
H
3.6
14.7
|
L
 114.0%
H
1.1
17.9
|
| Cue Biopharma Inc |
|
33.8
|
0.4
|
L
 -5.1%
H
0.4
0.4
|
L
 23.3%
H
0.3
0.5
|
L
 15.6%
H
0.3
0.5
|
L
 -52.0%
H
0.2
0.9
|
L
 -73.2%
H
0.2
1.5
|
L
 -89.2%
H
0.2
5.1
|
L
 -97.2%
H
0.2
18.4
|
L
H
0.2
31.7
|
| Cadrenal Therapeutics Inc |
|
17.9
|
7.7
|
L
 0.5%
H
7.5
8.0
|
L
 3.9%
H
6.9
8.2
|
L
 3.4%
H
6.4
8.8
|
L
 -41.5%
H
6.4
13.8
|
L
 -60.5%
H
6.4
22.9
|
L
 192.4%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
10.0
|
1.6
|
L
 -6.9%
H
1.6
1.7
|
L
 2.5%
H
1.6
1.9
|
L
 -10%
H
1.5
2.0
|
L
 -46.9%
H
1.5
3.3
|
L
 -80.5%
H
1.5
8.8
|
L
 -80.5%
H
1.5
10.8
|
L
 -98.9%
H
1.5
675.2
|
L
H
1.5
736
|
| Compass Pathways PLC (ADR) |
|
644.3
|
6.7
|
L
 -4.0%
H
6.6
7.0
|
L
 -8.2%
H
6.5
7.5
|
L
 0.5%
H
6.3
8.2
|
L
 2.6%
H
4.9
8.2
|
L
 85.9%
H
2.3
8.2
|
L
 -37.3%
H
2.3
12.8
|
L
 -84.6%
H
2.3
58.6
|
L
H
2.3
61.7
|
| Denali Therapeutics Inc |
|
3,254.3
|
20.8
|
L
 -1.9%
H
20.4
21.8
|
L
 18.9%
H
17.5
21.8
|
L
 23.5%
H
15.3
21.8
|
L
 28.6%
H
13.8
21.8
|
L
 -10.1%
H
10.6
24.3
|
L
 -33.8%
H
10.6
33.3
|
L
 -70.1%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
65.7
|
4.1
|
L
 -2.2%
H
4.1
4.3
|
L
 -2.4%
H
4.0
4.3
|
L
 -10.3%
H
4.0
5.1
|
L
 -32.3%
H
3.7
6.1
|
L
 105%
H
1.7
13.6
|
L
 5.1%
H
0.8
13.6
|
L
 -82.9%
H
0.8
43.4
|
L
 -97.3%
H
0.8
308.4
|
| DarioHealth Corp |
|
74.1
|
11.0
|
L
 -1.0%
H
10.6
11.7
|
L
 -11.9%
H
10.6
12.4
|
L
 9.2%
H
10.0
13.6
|
L
 -30.4%
H
9.0
16.4
|
L
 -19.5%
H
5.9
17.7
|
L
 -90.6%
H
5.9
119.2
|
L
 -97.5%
H
5.9
637
|
L
 -99.6%
H
5.9
3492
|
| Bright Minds Biosciences Inc |
|
780.9
|
80.2
|
L
 -5.6%
H
80.2
85.4
|
L
 -3.3%
H
80.2
91
|
L
 -2.3%
H
72.0
123.8
|
L
 36.5%
H
50
123.8
|
L
 167.2%
H
23.2
123.8
|
L
 2011.6%
H
0.9
123.8
|
L
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
577.0
|
10.1
|
L
 -4.3%
H
10.1
10.7
|
L
 7.2%
H
9.4
11.0
|
L
 5.2%
H
8.2
11.0
|
L
 45.3%
H
6.2
11.0
|
L
 100.2%
H
2.6
11.0
|
L
 22.5%
H
1.9
11.0
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
95.3
|
4.0
|
L
 -4.1%
H
3.9
4.1
|
L
 -5.0%
H
3.9
4.6
|
L
 -6.4%
H
3.8
4.6
|
L
 -44.9%
H
3.8
8.8
|
L
 -21.3%
H
3.8
8.8
|
L
 238.5%
H
0.3
19.4
|
L
 -66.9%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dynavax Tech Corp |
|
1,759.8
|
15.5
|
L
H
15.5
15.5
|
L
 -1.3%
H
15.5
15.7
|
L
 0.7%
H
15.4
15.7
|
L
 47.6%
H
9.9
15.7
|
L
 23.3%
H
9.2
15.7
|
L
 30.7%
H
9.2
15.7
|
L
 152.1%
H
5.9
21.4
|
L
 -36.5%
H
1.8
24.9
|
| Dyne Therapeutics Inc |
|
2,914.3
|
17.7
|
L
 -1.9%
H
17.3
18.2
|
L
 6.8%
H
16.4
18.6
|
L
 -11.7%
H
16
20.2
|
L
 -26.8%
H
16
25
|
L
 29.5%
H
6.4
25
|
L
 19.7%
H
6.4
47.5
|
L
 -3.8%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
201.1
|
2.1
|
L
 -2.4%
H
2.0
2.1
|
L
 2.0%
H
2.0
2.4
|
L
 -5.1%
H
1.9
2.4
|
L
 -36.6%
H
1.9
3.4
|
L
 46.1%
H
0.9
4.5
|
L
 -78.5%
H
0.9
11.9
|
L
 -96.6%
H
0.9
73.0
|
L
H
0.9
100.0
|
| Elicio Therapeutics Inc |
|
141.3
|
8.2
|
L
 -3.1%
H
8
8.5
|
L
 3.0%
H
7.9
8.5
|
L
 1.5%
H
7.5
9
|
L
 -15.6%
H
7.4
10.2
|
L
 1.2%
H
4.6
12.6
|
L
 17%
H
3.0
24.4
|
L
H
3.0
263
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
1,506.2
|
25.4
|
L
 -3.0%
H
25.3
26.1
|
L
 -6.2%
H
25.3
28.7
|
L
 55.7%
H
14.8
30.0
|
L
 18.6%
H
14.8
30.0
|
L
 19.2%
H
13.3
30.0
|
L
 55.1%
H
9.8
30.0
|
L
 -51.9%
H
3.9
59.9
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
246.4
|
5.2
|
L
 0.8%
H
4.7
5.3
|
L
 19.4%
H
4.1
5.3
|
L
 4.7%
H
3.5
5.3
|
L
 145.7%
H
1.6
5.3
|
L
 167.4%
H
1.1
5.3
|
L
 34.0%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
273.0
|
1.2
|
L
 -4.2%
H
1.1
1.2
|
L
 17.4%
H
0.9
1.3
|
L
 53.3%
H
0.7
1.3
|
L
 6.5%
H
0.7
1.8
|
L
H
0.7
2.1
|
L
 -74.0%
H
0.7
4.7
|
L
 -90.0%
H
0.7
29.4
|
L
 -99.1%
H
0.7
318
|
| Enochian Biosciences Inc |
|
-
|
0.8
|
L
 -4.8%
H
0.8
0.9
|
L
 -8.1%
H
0.8
1.0
|
L
 -17.5%
H
0.8
1.0
|
L
 -23.8%
H
0.8
1.7
|
L
 150%
H
0.1
1.7
|
L
 -25.9%
H
0.1
2.3
|
L
 -75.8%
H
0.1
13.8
|
L
 -46.7%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
2.9
|
0.8
|
L
 -7.1%
H
0.8
0.9
|
L
 -16.0%
H
0.8
0.9
|
L
 -28.2%
H
0.8
1.1
|
L
 -63.1%
H
0.8
2.2
|
L
 -89.2%
H
0.8
7.7
|
L
 -90.6%
H
0.1
9.9
|
L
 -100.0%
H
0.1
5757.6
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
85.3
|
1.4
|
L
 7.7%
H
1.2
1.4
|
L
 21.7%
H
1.1
1.4
|
L
 -6.7%
H
1.1
1.7
|
L
 2.2%
H
0.8
1.7
|
L
 100%
H
0.3
2.4
|
L
 38.6%
H
0.3
3.3
|
L
 -76.3%
H
0.3
11.3
|
L
H
0.3
27.1
|
| Edgewise Therapeutics Inc |
|
3,036.3
|
28.7
|
L
 -2.3%
H
28.3
29.6
|
L
 -0.2%
H
27.6
30.3
|
L
 8.8%
H
22.8
30.3
|
L
 78.9%
H
15.7
30.3
|
L
 3.0%
H
10.6
30.5
|
L
 162.9%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
| Evaxion Biotech A/S (ADR) |
|
29.6
|
3.6
|
L
 -11.5%
H
3.6
4.1
|
L
 -24.2%
H
3.6
4.7
|
L
 -30.8%
H
3.6
5.5
|
L
 -42.1%
H
3.6
6.9
|
L
 -40.8%
H
1.2
12.2
|
L
 -78.0%
H
0.8
21.1
|
L
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
139.6
|
1.2
|
L
 -7.6%
H
1.2
1.3
|
L
 10%
H
1.1
1.3
|
L
 21%
H
1.0
1.3
|
L
 -21.9%
H
1.0
1.6
|
L
 -11.7%
H
0.7
1.9
|
L
 -79.6%
H
0.7
8.8
|
L
 -98.6%
H
0.7
118.1
|
L
 -44.7%
H
0.7
121.2
|
| Forte Biosciences Inc |
|
373.9
|
29.9
|
L
 -16.0%
H
29.2
35.4
|
L
 -1.8%
H
29.2
35.6
|
L
 7.1%
H
21.9
35.6
|
L
 129.6%
H
10.3
35.6
|
L
 95.9%
H
4.9
35.6
|
L
 18.2%
H
4.1
35.6
|
L
 -96.5%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
438.7
|
8.6
|
L
 1.3%
H
8.3
8.8
|
L
 12.9%
H
7.5
8.8
|
L
 7.9%
H
7.0
8.8
|
L
 -29.9%
H
7.0
12.3
|
L
 82.2%
H
2.2
12.3
|
L
 -59.5%
H
2.2
36.3
|
L
 -80.0%
H
2.2
55.1
|
L
H
2.2
55.1
|
| Foghorn Therapeutics Inc |
|
343.9
|
5.9
|
L
 -0.5%
H
5.7
5.9
|
L
 5.4%
H
5.6
6.3
|
L
 8.7%
H
4.6
7.0
|
L
 42.5%
H
3.3
7.0
|
L
 42.5%
H
2.9
7.0
|
L
 -31.0%
H
2.7
10.2
|
L
 -66.3%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Frequency Therapeutics Inc |
|
-
|
11.7
|
L
 8.9%
H
11.0
12.4
|
L
 36.3%
H
8.5
12.4
|
L
 44.0%
H
7.7
12.4
|
L
 -70.5%
H
5.2
42.7
|
L
 -22.6%
H
5.2
55.9
|
L
 -95.1%
H
5.2
240
|
L
 -99.4%
H
5.2
2918.5
|
L
H
5.2
2918.5
|
| First Wave BioPharma Inc |
|
4.7
|
3
|
L
 -10.7%
H
3.0
3.4
|
L
 -8.5%
H
2.7
3.7
|
L
 0.7%
H
2.7
5.3
|
L
 -26.7%
H
1.9
5.3
|
L
 614.3%
H
0.4
5.8
|
L
 -97.2%
H
0.4
132.7
|
L
 -100.0%
H
0.4
86009.8
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
198.6
|
3.1
|
L
 -2.2%
H
3.1
3.2
|
L
 3.0%
H
2.9
3.6
|
L
 -24.0%
H
2.9
4.4
|
L
 -39.6%
H
2.9
7.1
|
L
 152.5%
H
1.1
7.1
|
L
 177.5%
H
0.7
7.1
|
L
 54%
H
0.7
7.1
|
L
 109.5%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
75.4
|
2.0
|
L
 -4.9%
H
2.0
2.1
|
L
 -1.5%
H
1.9
2.1
|
L
 -37.8%
H
1.8
3.3
|
L
 0.5%
H
1.7
4.3
|
L
 -8.4%
H
1.4
4.3
|
L
 -51.8%
H
0.9
6.2
|
L
H
0.9
17.9
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
9.6
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 -21.9%
H
0.7
1.1
|
L
 -46.4%
H
0.7
1.6
|
L
 -66.1%
H
0.7
3.1
|
L
 -66.9%
H
0.7
3.7
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
849.0
|
1.3
|
L
 -3.6%
H
1.3
1.4
|
L
 2.3%
H
1.3
1.4
|
L
 -2.9%
H
1.3
1.5
|
L
 3.9%
H
1.0
1.5
|
L
 -55.1%
H
1.0
3.1
|
L
 -60.2%
H
1.0
5.3
|
L
 -23.1%
H
1.0
5.3
|
L
 -57.1%
H
0.8
7.0
|
| Gilead Sciences |
|
173,347.8
|
139.7
|
L
 -0.9%
H
138.7
140.9
|
L
 12.6%
H
122.7
141.7
|
L
 12.0%
H
116.9
141.7
|
L
 16.0%
H
114.0
141.7
|
L
 46.5%
H
93.4
141.7
|
L
 66.9%
H
62.1
141.7
|
L
 113.4%
H
57.2
141.7
|
L
 55.9%
H
56.6
141.7
|
| Greenwich LifeSciences Inc |
|
396.1
|
28.6
|
L
 -14.8%
H
28.6
33.3
|
L
 34.3%
H
20
34.1
|
L
 38.3%
H
18.5
34.1
|
L
 192.0%
H
7.8
34.1
|
L
 115.3%
H
7.8
34.1
|
L
 47.8%
H
7.6
34.1
|
L
 -16.4%
H
6.8
69.8
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,611.0
|
21.1
|
L
 -8.5%
H
21.1
23.2
|
L
 -13.5%
H
21.1
25.4
|
L
 22.2%
H
13.7
25.8
|
L
 71.5%
H
11.5
25.8
|
L
 267.5%
H
3.5
25.8
|
L
 183.6%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
4.9
|
2.8
|
L
H
2.8
3.0
|
L
 1.8%
H
2.7
3.4
|
L
 -37.2%
H
2.6
5.6
|
L
 -80.2%
H
2.6
15.2
|
L
 -94.1%
H
2.6
51.3
|
L
 -99.1%
H
2.6
367.5
|
L
 -99.9%
H
2.6
3266.3
|
L
 -100.0%
H
2.6
379518072.3
|
| Graphite Bio Inc |
|
1,086.1
|
18.7
|
L
 -3.8%
H
18.5
19.8
|
L
 -3.8%
H
18.5
21.8
|
L
 10.6%
H
14.4
21.8
|
L
 -40.4%
H
14.4
32.1
|
L
 -30.4%
H
14.4
50.4
|
L
 -80.4%
H
14.4
413
|
L
H
14.4
1666
|
L
H
14.4
1666
|
| Galapagos NV (ADR) |
|
2,247.1
|
34.1
|
L
 -1.6%
H
34.1
34.6
|
L
 1.9%
H
33.2
35.1
|
L
 3.2%
H
31.7
35.1
|
L
 9.9%
H
29.8
35.1
|
L
 44.4%
H
22.4
37.8
|
L
 -22.8%
H
22.4
45.2
|
L
 -68.7%
H
22.4
109.7
|
L
 -33.9%
H
22.4
274.0
|
| Halozyme Therapeutics Inc |
|
8,564.6
|
72.8
|
L
 3.7%
H
70.1
73.2
|
L
 3.4%
H
68.9
73.2
|
L
 5.8%
H
67.0
75.6
|
L
 10.6%
H
61.2
75.6
|
L
 30.4%
H
47.5
79.5
|
L
 43.6%
H
29.9
79.5
|
L
 54.8%
H
29.9
79.5
|
L
 720.2%
H
7.0
79.5
|
| HCW Biologics Inc |
|
4.0
|
1.2
|
L
 -4.7%
H
1.2
1.3
|
L
 -9.6%
H
1.2
1.7
|
L
 -14.1%
H
1.0
1.7
|
L
 -68.3%
H
1.0
3.9
|
L
 -90.8%
H
0.2
41.2
|
L
 -98.5%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
47.5
|
4.1
|
L
 12.8%
H
3.6
4.2
|
L
 38.7%
H
2.7
4.2
|
L
 56.4%
H
2.6
4.2
|
L
 31.1%
H
2.2
6.9
|
L
 204.5%
H
1.1
9.1
|
L
 -73%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
243.9
|
1.3
|
L
 -5%
H
1.3
1.4
|
L
 -6.3%
H
1.3
1.5
|
L
 3.9%
H
1.2
1.6
|
L
 12.7%
H
1
1.6
|
L
 -26.5%
H
1
2.7
|
L
 -52.3%
H
0.5
3.9
|
L
 -92.5%
H
0.5
20.5
|
L
 -94.2%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
18.9
|
4.9
|
L
 -4.7%
H
4.8
5.3
|
L
 -32.0%
H
4.8
7.2
|
L
 -40.8%
H
4.8
8.4
|
L
 -63.4%
H
4.8
13.9
|
L
 68.7%
H
2.9
38.3
|
L
 -92.1%
H
2.7
136.5
|
L
 -96.1%
H
2.7
288.6
|
L
H
2.7
11431.9
|
| Humacyte Inc |
|
193.0
|
1
|
L
 -2.9%
H
1.0
1.1
|
L
 -2.0%
H
1.0
1.2
|
L
 -6.5%
H
0.9
1.3
|
L
 -40.5%
H
0.9
1.8
|
L
 -77.8%
H
0.9
4.9
|
L
 -64.0%
H
0.9
10.0
|
L
 -90.0%
H
0.9
17.5
|
L
H
0.9
17.5
|
| Immucell Corp |
|
57.5
|
6.4
|
L
 1.6%
H
6.2
6.5
|
L
 -2.5%
H
6.2
6.9
|
L
 3.9%
H
5.8
6.9
|
L
 1.9%
H
4.5
7.1
|
L
 21.4%
H
4.3
7.6
|
L
 -14.1%
H
3.3
7.7
|
L
 -14.6%
H
3.3
13.2
|
L
 -17.0%
H
3.3
13.2
|
| InflaRx N.V. |
|
61.6
|
0.9
|
L
 -6.2%
H
0.9
1.0
|
L
 -8.1%
H
0.9
1.1
|
L
 -17.3%
H
0.9
1.2
|
L
 -45.2%
H
0.9
1.9
|
L
 -60.1%
H
0.7
2.8
|
L
 -59.6%
H
0.7
7.3
|
L
 -83.8%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
82.6
|
7.4
|
L
 0.5%
H
7.2
7.4
|
L
 17.3%
H
6.2
7.4
|
L
 27.4%
H
5.7
7.4
|
L
 -11.5%
H
5.7
9.1
|
L
 -59.5%
H
5.7
19.2
|
L
 -86.3%
H
5.7
91.7
|
L
H
5.7
451.3
|
L
H
5.7
451.3
|
| Illumina Inc |
|
22,898.6
|
149.9
|
L
 -1.5%
H
148.5
152.8
|
L
 1.8%
H
147.3
155.5
|
L
 11.1%
H
130.4
155.5
|
L
 49.3%
H
94
155.5
|
L
 8.6%
H
68.7
155.5
|
L
 -30.0%
H
68.7
238.6
|
L
 -65.3%
H
68.7
555.8
|
L
 -7.7%
H
68.7
555.8
|
| Immunome Inc |
|
2,730.8
|
24.8
|
L
 -3.7%
H
24.7
25.9
|
L
 3.6%
H
23.5
26.6
|
L
 14%
H
19.2
26.6
|
L
 49.1%
H
14.6
26.6
|
L
 155.4%
H
5.2
26.6
|
L
 369.6%
H
4.0
31.0
|
L
 61.3%
H
2.1
63.8
|
L
H
2.1
63.8
|
| Imunon Inc |
|
11.6
|
3.4
|
L
 -6.6%
H
3.4
3.6
|
L
 -1.7%
H
3.4
3.9
|
L
 7.9%
H
3.0
4.2
|
L
 -28.0%
H
3.0
4.9
|
L
 -75.8%
H
3.0
47.4
|
L
 -85.5%
H
3.0
54.8
|
L
 -99.0%
H
3.0
783
|
L
 -99.9%
H
3.0
5607
|
| Immatics N.V |
|
1,300.4
|
9.7
|
L
 -2.9%
H
9.6
10.1
|
L
 -1.7%
H
9.4
10.4
|
L
 -5.1%
H
8.9
10.9
|
L
 -8.3%
H
8.7
12.4
|
L
 76.0%
H
3.3
12.4
|
L
 22.5%
H
3.3
13.8
|
L
 -6.2%
H
3.3
18.4
|
L
H
3.3
18.4
|
| Immunovant Inc |
|
5,250.5
|
26.1
|
L
 -2.9%
H
26.0
26.9
|
L
 -0.3%
H
25.3
27.4
|
L
 -0.4%
H
24.7
27.8
|
L
 21.6%
H
21.1
27.8
|
L
 16.3%
H
12.7
27.8
|
L
 47.1%
H
12.7
45.6
|
L
 -31.5%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
19.1
|
2.0
|
L
 -5.3%
H
2.0
2.2
|
L
 -17.0%
H
2.0
2.5
|
L
 -12.1%
H
1.9
2.7
|
L
 -6.7%
H
1.2
2.7
|
L
 625.9%
H
0.1
4.2
|
L
 -14.0%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
3,505.0
|
74.0
|
L
 0.7%
H
71.9
76.7
|
L
 1.5%
H
71.3
82.2
|
L
 -7.8%
H
69.5
82.3
|
L
 25.7%
H
57.8
94.6
|
L
 496.1%
H
10.8
94.6
|
L
 172.6%
H
10.8
94.6
|
L
 143.8%
H
7.7
94.6
|
L
H
7.7
94.6
|
| MiNK Therapeutics Inc |
|
58.9
|
12.5
|
L
 -2.3%
H
12.4
12.9
|
L
 6.1%
H
11.6
12.9
|
L
 4.9%
H
10.8
12.9
|
L
 -13.8%
H
10.5
14.5
|
L
 41.9%
H
4.6
76
|
L
 -44.0%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
42.8
|
1.6
|
L
 -10.6%
H
1.6
1.8
|
L
 0.6%
H
1.6
1.8
|
L
 -6.9%
H
1.4
1.8
|
L
 -12.5%
H
1.4
2.3
|
L
 -79.7%
H
1.4
11.6
|
L
 -80.7%
H
1.4
14.7
|
L
 -91.4%
H
1.4
30.4
|
L
H
1.4
30.4
|
| IO Biotech Inc |
|
22.3
|
0.3
|
L
 -6.1%
H
0.3
0.3
|
L
 -40.4%
H
0.2
0.6
|
L
 -58.1%
H
0.2
0.7
|
L
 -65.9%
H
0.2
1.1
|
L
 -68.0%
H
0.2
2.8
|
L
 -89.0%
H
0.2
3.0
|
L
H
0.2
17.9
|
L
H
0.2
17.9
|
| Iovance Biotherapeutics Inc |
|
1,091.7
|
2.8
|
L
 -7.7%
H
2.7
3.0
|
L
 12.7%
H
2.4
3.0
|
L
 -3.5%
H
2.2
3.0
|
L
 19.1%
H
1.8
3.0
|
L
 -56%
H
1.6
6.4
|
L
 -66.3%
H
1.6
18.3
|
L
 -93.5%
H
1.6
53.0
|
L
 -54.0%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
206.3
|
2.4
|
L
 -10.9%
H
2.3
2.7
|
L
 22.9%
H
1.8
2.7
|
L
 118.5%
H
0.9
2.7
|
L
 293.3%
H
0.4
2.7
|
L
 168.2%
H
0.3
2.7
|
L
 -49.0%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
3,020.4
|
80.0
|
L
 -2.6%
H
79.1
82.2
|
L
 8.1%
H
73.8
82.3
|
L
 -0.4%
H
69.2
82.3
|
L
 -10.8%
H
69.2
99.5
|
L
 43.0%
H
30.8
99.5
|
L
 262.2%
H
18.3
99.5
|
L
 -32.7%
H
11.6
190.9
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
541.4
|
1.9
|
L
 -5.4%
H
1.9
2.1
|
L
 -14.3%
H
1.9
2.3
|
L
 -28.6%
H
1.9
2.8
|
L
 -10.7%
H
1.4
3.1
|
L
 368.3%
H
0.4
3.1
|
L
 -22.6%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,674.1
|
33.1
|
L
 -5.5%
H
32.6
35.2
|
L
 -0.6%
H
32.6
36.0
|
L
 -8.3%
H
31.8
36.6
|
L
 -1.0%
H
30.5
40.7
|
L
 2.7%
H
23.2
40.7
|
L
 -45.4%
H
23.2
77.0
|
L
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
450.4
|
3.1
|
L
 -0.7%
H
3.0
3.1
|
L
 8.9%
H
2.7
3.2
|
L
 -2.2%
H
2.7
3.2
|
L
 50%
H
1.7
3.5
|
L
 57.7%
H
1.3
3.5
|
L
 53%
H
1.3
3.9
|
L
H
1.3
5.4
|
L
 -4.4%
H
0.5
8.0
|
| Inventiva (ADR) |
|
1,310.9
|
6.8
|
L
 -0.6%
H
6.8
7.2
|
L
 6.2%
H
6.2
7.3
|
L
 52.5%
H
4.5
7.3
|
L
 -1.0%
H
3.6
8.0
|
L
 199.6%
H
2.2
8.0
|
L
 12.9%
H
1.5
8.0
|
L
 -53.6%
H
1.5
17.9
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
839.1
|
14.0
|
L
 -5.3%
H
14.0
14.8
|
L
 6.1%
H
13.1
15.5
|
L
 -2.1%
H
12.8
15.5
|
L
 -49.0%
H
12.8
35.3
|
L
 -68.0%
H
12.8
46.1
|
L
 -36.6%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
44.5
|
1.6
|
L
 -3.1%
H
1.6
1.7
|
L
 3.3%
H
1.5
1.7
|
L
 -9.7%
H
1.4
2.1
|
L
 -31.8%
H
1.4
2.5
|
L
 -72.0%
H
1.4
7.2
|
L
 -8.6%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kamada Ltd |
|
498.4
|
8.6
|
L
 -2.6%
H
8.6
8.9
|
L
 10.6%
H
7.7
8.9
|
L
 22.2%
H
6.9
8.9
|
L
 22.9%
H
6.6
8.9
|
L
 25.2%
H
5.5
9.2
|
L
 94.2%
H
4.1
9.2
|
L
 32.7%
H
3.7
9.2
|
L
 134.1%
H
3.3
13.3
|
| Kodiak Sciences Inc |
|
1,591.5
|
26.1
|
L
 6.3%
H
23.7
26.8
|
L
 -2.1%
H
23.7
29.5
|
L
 -12.8%
H
23.7
30.0
|
L
 38.5%
H
15.8
31.2
|
L
 245.8%
H
1.9
31.2
|
L
 230.8%
H
1.4
31.2
|
L
 -80.6%
H
1.4
171.2
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
7,913.7
|
272.9
|
L
 -1.6%
H
272.2
279.6
|
L
 -0.7%
H
271.7
294.6
|
L
 8.2%
H
235.6
296.0
|
L
 43.7%
H
183.3
296.0
|
L
 71.6%
H
122.8
296.0
|
L
 224.0%
H
70.5
296.0
|
L
 304.7%
H
38.9
296.0
|
L
H
8.0
296.0
|
| TuHURA Biosciences Inc |
|
32.2
|
0.6
|
L
 -9.5%
H
0.5
0.6
|
L
 -16.2%
H
0.5
0.7
|
L
 -28.8%
H
0.5
0.8
|
L
 -75.2%
H
0.5
2.6
|
L
 -86.4%
H
0.5
5.3
|
L
 -99.8%
H
0.2
253.8
|
L
 -100.0%
H
0.2
5862.5
|
L
 -100.0%
H
0.2
190225
|
| Kura Oncology Inc |
|
699.6
|
8.0
|
L
 -5.1%
H
8.0
8.5
|
L
 -6.5%
H
8.0
9.2
|
L
 -24.4%
H
8.0
10.6
|
L
 -27.2%
H
8.0
12.5
|
L
 1.6%
H
5.4
12.5
|
L
 -41.1%
H
5.4
24.2
|
L
 -73.0%
H
5.4
36.0
|
L
 68.6%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
5,692.7
|
71.2
|
L
 -1.4%
H
70.6
73.6
|
L
 4.4%
H
67.8
73.6
|
L
 -12.5%
H
66.2
81.9
|
L
 16.9%
H
55.7
103
|
L
 72.6%
H
19.4
103
|
L
 93.1%
H
9.6
103
|
L
 9.4%
H
9.6
103
|
L
H
9.6
103
|
| Kezar Life Sciences Inc |
|
45.0
|
6.2
|
L
 -1.3%
H
6.1
6.2
|
L
H
6.1
6.3
|
L
 -3%
H
6.0
6.5
|
L
 -0.7%
H
6.0
6.5
|
L
 -3.2%
H
3.5
6.7
|
L
 -91.1%
H
0.7
74.4
|
L
 -88.5%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Longeveron Inc (Class A) |
|
12.6
|
0.6
|
L
 1.7%
H
0.6
0.6
|
L
 11.3%
H
0.5
0.7
|
L
 11.3%
H
0.5
0.7
|
L
 -35.9%
H
0.5
0.9
|
L
 -62.9%
H
0.5
1.9
|
L
 -98.6%
H
0.5
44
|
L
H
0.5
450
|
L
H
0.5
450
|
| Lixte biotech Holdings Inc |
|
32.3
|
3.7
|
L
 8.5%
H
3.4
3.8
|
L
 22.0%
H
2.9
3.8
|
L
 -8.9%
H
2.9
4.1
|
L
 -10.6%
H
2.9
5.0
|
L
 56.5%
H
0.6
6.3
|
L
 -49.2%
H
0.6
27
|
L
 -88.5%
H
0.6
71.9
|
L
 -71.9%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
45.3
|
0.8
|
L
 -8.1%
H
0.8
0.9
|
L
 -13.0%
H
0.8
1.0
|
L
 -33.3%
H
0.8
1.3
|
L
 63.3%
H
0.4
3.7
|
L
 -64.4%
H
0.2
3.7
|
L
 -87.5%
H
0.2
10.2
|
L
 -96.5%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
305.8
|
3.7
|
L
 0.3%
H
3.6
3.8
|
L
 15%
H
3.2
3.8
|
L
 -6.4%
H
3.1
4
|
L
 -15.2%
H
3.1
4.5
|
L
 6.4%
H
1.6
5.4
|
L
 -21.2%
H
1.6
13.7
|
L
 -77%
H
1.5
20.6
|
L
 -95.7%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
510.5
|
24.0
|
L
 -4.9%
H
24.0
26.0
|
L
 0.5%
H
23.5
27.9
|
L
 -31.5%
H
22.4
37
|
L
 39.5%
H
15.7
45
|
L
 91.6%
H
7.7
45
|
L
 -64.0%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
127.6
|
1.9
|
L
 -3.6%
H
1.9
2.0
|
L
 -8.7%
H
1.9
2.1
|
L
 -11.6%
H
1.9
2.2
|
L
 -20.5%
H
1.7
2.6
|
L
 -5%
H
1.3
4.7
|
L
 -40.4%
H
0.8
4.7
|
L
 -79.6%
H
0.8
10.7
|
L
 -99.7%
H
0.8
729
|
| Seres Therapeutics Inc |
|
137.0
|
15.1
|
L
 -1.9%
H
15
15.6
|
L
 0.5%
H
14.5
15.9
|
L
 3.3%
H
14.0
16.4
|
L
 -11.8%
H
12.5
30.0
|
L
 1702.4%
H
0.4
30.0
|
L
 173.8%
H
0.4
30.0
|
L
 -33.7%
H
0.4
30.0
|
L
 -39.2%
H
0.4
38.5
|
| MeiraGTx Holdings PLC |
|
624.6
|
7.8
|
L
 -3.1%
H
7.7
8
|
L
 6.0%
H
7.3
8.3
|
L
 -2.6%
H
7
8.3
|
L
 -12.5%
H
7
9.7
|
L
 25.6%
H
4.6
9.7
|
L
 -2.4%
H
3.5
9.7
|
L
 -47.5%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,559.4
|
32.3
|
L
 -1.5%
H
31.8
33.0
|
L
 1.3%
H
31.0
34.7
|
L
 -12.9%
H
31.0
37.7
|
L
 -20.3%
H
31.0
47.7
|
L
 223.4%
H
8.2
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
450.7
|
67.4
|
L
 -4.1%
H
65.3
70.9
|
L
 -4.1%
H
65.3
76.1
|
L
 -1.9%
H
56.2
76.1
|
L
 -17.0%
H
56.2
100.5
|
L
 101.2%
H
26.1
105
|
L
 285.4%
H
1.4
105
|
L
 104.4%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
27.2
|
1.6
|
L
 -9.4%
H
1.6
1.8
|
L
 -23.1%
H
1.6
2.3
|
L
 13.2%
H
1.4
2.5
|
L
 59.8%
H
0.8
2.5
|
L
 -15.5%
H
0.8
4.1
|
L
 -47.8%
H
0.7
9.7
|
L
 -91.5%
H
0.7
37.7
|
L
 -97.8%
H
0.7
135.5
|
| Moderna |
|
17,700.2
|
45.3
|
L
 -0.3%
H
43.6
46.0
|
L
 5.4%
H
43.3
55.2
|
L
 45.2%
H
29.1
55.2
|
L
 69.9%
H
22.3
55.2
|
L
 8.8%
H
22.3
55.2
|
L
 -76.1%
H
22.3
187.6
|
L
 -70.9%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
496.0
|
3.4
|
L
 -10%
H
3.4
3.8
|
L
 -8.8%
H
3.4
4.0
|
L
 4.6%
H
3.2
4.1
|
L
 2.4%
H
2.5
4.1
|
L
 -39.0%
H
1.7
6.1
|
L
 -76.4%
H
1.7
16.9
|
L
 -88.4%
H
1.7
63.6
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
107.7
|
1.0
|
L
 -5.6%
H
1.0
1.1
|
L
 -16.5%
H
1.0
1.3
|
L
 -37.3%
H
1.0
1.6
|
L
 -34.4%
H
1.0
1.8
|
L
 -77.7%
H
1.0
4.9
|
L
 -82.5%
H
1.0
6.0
|
L
 -89.2%
H
1.0
17.4
|
L
H
1.0
17.4
|
| Mainz Biomed N.V. |
|
10.8
|
1.2
|
L
 -2.5%
H
1.2
1.3
|
L
 8.2%
H
1.1
1.6
|
L
 -6.3%
H
1.1
1.6
|
L
 -25.6%
H
0.9
2.1
|
L
 -75.9%
H
0.9
8.2
|
L
 -99.5%
H
0.9
300
|
L
H
0.9
1200
|
L
H
0.9
1200
|
| Mesoblast Ltd (ADR) |
|
2,412.8
|
18.7
|
L
 -2.5%
H
18.5
19.2
|
L
 11.1%
H
16.8
19.3
|
L
 -4.1%
H
16.7
21.5
|
L
 11.9%
H
14.1
21.5
|
L
 4.6%
H
9.6
21.5
|
L
 461.6%
H
1.0
22
|
L
 109.2%
H
1.0
22
|
L
 243.8%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
155.6
|
4.2
|
L
 4%
H
4.0
4.3
|
L
 2.7%
H
4.0
4.3
|
L
 -1.7%
H
4.0
4.5
|
L
 15.9%
H
3.6
4.8
|
L
 -21.7%
H
3.4
5.4
|
L
 -36.8%
H
3.3
12.7
|
L
 -80.7%
H
3.3
32.0
|
L
 -87.5%
H
3.3
34.5
|
| Mereo Biopharma Grp PLC (ADR) |
|
71.6
|
0.5
|
L
 -4.3%
H
0.4
0.5
|
L
 -19.6%
H
0.4
0.6
|
L
 -80.5%
H
0.2
0.8
|
L
 -77.5%
H
0.2
2.4
|
L
 -84.6%
H
0.2
3.3
|
L
 -55%
H
0.2
5.0
|
L
 -83.3%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
260.2
|
2.1
|
L
 -7.6%
H
2.1
2.3
|
L
 0.5%
H
2
2.3
|
L
 4.0%
H
1.8
2.3
|
L
 52.6%
H
1.3
2.5
|
L
 12.0%
H
0.6
2.5
|
L
 3.5%
H
0.6
4.7
|
L
 -81.6%
H
0.6
25.9
|
L
H
0.6
25.9
|
| Nkarta Inc |
|
175.4
|
2.5
|
L
 -2.8%
H
2.4
2.6
|
L
 21.1%
H
2.0
2.6
|
L
 34.2%
H
1.8
2.6
|
L
 5.1%
H
1.7
2.6
|
L
 2.1%
H
1.3
2.7
|
L
 -51.0%
H
1.3
16.2
|
L
 -94.4%
H
1.3
58.8
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
19.3
|
L
 -3.0%
H
19.0
20.4
|
L
 10.0%
H
17.5
20.4
|
L
 -3.7%
H
16.5
23.0
|
L
 -39.9%
H
16.5
35.5
|
L
 7.1%
H
14.7
37.3
|
L
 60.6%
H
9.8
37.3
|
L
 -92.4%
H
7.5
298
|
L
 -91.4%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
8.4
|
L
 0.4%
H
8.4
8.7
|
L
 1.4%
H
8.1
8.7
|
L
 15.8%
H
7.2
8.8
|
L
 21.8%
H
6.4
8.8
|
L
 18.5%
H
6.2
8.8
|
L
 298.1%
H
0.0
8.8
|
L
 -62.0%
H
0.0
45.2
|
L
H
0.0
1010
|
| MetaVia Inc |
|
7.8
|
2.3
|
L
 -10%
H
2.3
2.7
|
L
 -22%
H
2.3
3.1
|
L
 -74.5%
H
2.3
9.6
|
L
 -78.0%
H
2.3
14.9
|
L
 -88.6%
H
2.3
23.5
|
L
 -96.7%
H
2.3
83.6
|
L
 -100.0%
H
2.3
17344.8
|
L
H
2.3
1424940
|
| Intellia Therapeutics Inc |
|
1,600.8
|
13.8
|
L
 -6.8%
H
13.6
15
|
L
 7.7%
H
12.9
17.1
|
L
 46.4%
H
8.9
17.1
|
L
 -6.6%
H
8.0
17.1
|
L
 31%
H
5.9
28.3
|
L
 -66.8%
H
5.9
47.5
|
L
 -76.2%
H
5.9
202.7
|
L
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
7,786.7
|
100.3
|
L
 -5.8%
H
100.2
107.5
|
L
 -5.3%
H
100.2
113.0
|
L
 -3.7%
H
95.5
113.0
|
L
 2.6%
H
89.0
113.0
|
L
 21.4%
H
55.5
113.0
|
L
 208.9%
H
23.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,499.9
|
9.2
|
L
 -6.0%
H
9.2
9.9
|
L
 12.6%
H
8.2
10.2
|
L
 35.1%
H
6.6
10.2
|
L
 6.1%
H
6.2
10.2
|
L
 -1.0%
H
5.0
10.6
|
L
 -18.2%
H
3.5
23.9
|
L
 -93.0%
H
3.5
331.7
|
L
 -91.4%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
12.3
|
3.0
|
L
H
2.9
3.0
|
L
 -8.1%
H
2.9
3.4
|
L
 -10.9%
H
2.9
3.8
|
L
 -31.7%
H
2.9
4.6
|
L
 -100.0%
H
2.8
53600
|
L
 -100.0%
H
2.8
1750000
|
L
 -100.0%
H
2.8
6500000
|
L
H
2.8
32000000
|
| Insight Molecular Diagnostics Inc |
|
197.2
|
6.9
|
L
 -0.2%
H
6.7
7.0
|
L
 11.9%
H
6.0
7.0
|
L
 8.0%
H
6.0
7.5
|
L
 5.9%
H
4.7
8.5
|
L
 238.9%
H
1.9
8.5
|
L
 -19.1%
H
1.9
9.2
|
L
 -92.3%
H
1.9
131.4
|
L
 -86.9%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
82.4
|
2.2
|
L
 2.8%
H
2.1
2.5
|
L
 1.9%
H
2.0
2.5
|
L
 10.1%
H
1.9
3.2
|
L
 -17.4%
H
1.7
3.2
|
L
 110.6%
H
0.9
3.4
|
L
 -1.4%
H
0.8
7
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
119.4
|
1.1
|
L
 -4.3%
H
1.1
1.2
|
L
 12.1%
H
1.0
1.3
|
L
 16.8%
H
0.9
1.3
|
L
 -8.3%
H
0.9
1.3
|
L
 52.1%
H
0.3
1.5
|
L
 -39.0%
H
0.3
3.4
|
L
 -53.6%
H
0.3
4.8
|
L
 -58.1%
H
0.3
8.5
|
| Traws Pharma Inc |
|
19.7
|
2.5
|
L
 -12.8%
H
2.2
2.9
|
L
 -4.7%
H
2.2
3.0
|
L
 110.3%
H
1.1
3.0
|
L
 -5.4%
H
1.1
3.1
|
L
 -65.1%
H
1.0
8.6
|
L
 -88.4%
H
1.0
37.3
|
L
 -99.0%
H
1.0
723.8
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
4.5
|
1.7
|
L
 -3.9%
H
1.7
1.8
|
L
 -16.0%
H
1.7
2.2
|
L
 -13.9%
H
1.7
2.3
|
L
 -24.5%
H
1.7
3.2
|
L
 -60.0%
H
0.3
22.0
|
L
 -90.9%
H
0.3
40.8
|
L
 -98.9%
H
0.3
287.0
|
L
 -99.6%
H
0.3
1197.6
|
| Passage Bio Inc |
|
36.0
|
11.3
|
L
 -10%
H
10.2
12.5
|
L
 -11.2%
H
10.2
14.1
|
L
 4.4%
H
9.6
20
|
L
 57.5%
H
6.2
20
|
L
 -7.5%
H
5.1
20
|
L
 -62.9%
H
5.1
35.8
|
L
 -97.1%
H
5.1
465
|
L
H
5.1
764.6
|
| Vaxcyte Inc |
|
6,724.7
|
51.4
|
L
 -5.5%
H
50.5
54.8
|
L
 8.1%
H
46.9
56.0
|
L
 9.4%
H
43.9
56.0
|
L
 15.3%
H
39.9
56.0
|
L
 -43.5%
H
27.7
93.8
|
L
 11.3%
H
27.7
121.1
|
L
 109.2%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
358.9
|
5.2
|
L
 -6.8%
H
5.1
5.6
|
L
 -12.3%
H
5.1
6.1
|
L
 -10.2%
H
4.8
7.8
|
L
 -3.9%
H
4.1
7.8
|
L
 180.7%
H
0.9
7.8
|
L
 -67.6%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,578.1
|
4.5
|
L
 -5.7%
H
4.4
4.9
|
L
 1.6%
H
4.3
5.1
|
L
 7.2%
H
3.9
5.1
|
L
 3.7%
H
3.4
5.2
|
L
 243.1%
H
1.1
5.2
|
L
 172.0%
H
0.7
5.2
|
L
 -51.9%
H
0.7
9.8
|
L
 -83.1%
H
0.7
40.2
|
| Phio Pharma Corp |
|
11.0
|
1.0
|
L
 -1.0%
H
1.0
1.1
|
L
 -5.6%
H
1.0
1.1
|
L
 -5.6%
H
1.0
1.2
|
L
 -52.8%
H
1
4.2
|
L
 -49.5%
H
1.0
4.2
|
L
 -98.2%
H
0.6
110.4
|
L
 -99.7%
H
0.6
470.9
|
L
 -100.0%
H
0.6
196020
|
| Pliant Therapeutics Inc |
|
76.8
|
1.3
|
L
 -1.6%
H
1.3
1.3
|
L
 -2.3%
H
1.2
1.4
|
L
 3.3%
H
1.2
1.4
|
L
 -30.6%
H
1.2
1.8
|
L
 -88.6%
H
1.1
12.8
|
L
 -96.4%
H
1.1
35.7
|
L
 -95.2%
H
1.1
43.9
|
L
H
1.1
43.9
|
| Pluri Inc |
|
30.7
|
3.3
|
L
 0.6%
H
3.3
3.4
|
L
 7.8%
H
3
3.5
|
L
 6.8%
H
2.9
3.5
|
L
 -14.9%
H
2.8
4.9
|
L
 -24.6%
H
2.8
7.1
|
L
 -63.9%
H
0.7
9.4
|
L
 -94.1%
H
0.7
68.8
|
L
 -95.2%
H
0.7
169.6
|
| Prelude Therapeutics Inc |
|
123.8
|
2.0
|
L
 -7.1%
H
2.0
2.2
|
L
 7.1%
H
1.8
2.3
|
L
 -19.6%
H
1.8
3
|
L
 15.2%
H
1.2
4.2
|
L
 74.3%
H
0.6
4.2
|
L
 -69.3%
H
0.6
8.6
|
L
 -97.0%
H
0.6
95.4
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
727.5
|
4.0
|
L
 -5.8%
H
4.0
4.4
|
L
 3.6%
H
3.8
4.7
|
L
 15.1%
H
3.3
4.7
|
L
 -21.8%
H
3.2
5.1
|
L
 33%
H
1.1
6.9
|
L
 -76.9%
H
1.1
21.5
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
297.2
|
2.1
|
L
 -5.0%
H
2.1
2.2
|
L
 -1.9%
H
2.1
2.3
|
L
 -17%
H
2.1
2.6
|
L
 -34.8%
H
2.0
3.3
|
L
 27.3%
H
0.5
7.1
|
L
 -79.2%
H
0.5
14.2
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
492.0
|
9.1
|
L
 -6.1%
H
9.1
9.8
|
L
 -1.2%
H
9.1
10.5
|
L
 -4.2%
H
8.7
10.5
|
L
 -11.9%
H
8.7
11.7
|
L
 -43.0%
H
4.3
16.7
|
L
 -84.0%
H
4.3
79.7
|
L
 -24.3%
H
4.3
79.8
|
L
 -75.7%
H
4.3
79.8
|
| AlphaTON Cap Corp |
|
8.8
|
0.7
|
L
 10%
H
0.6
0.7
|
L
 -28.3%
H
0.6
0.8
|
L
H
0.6
3.3
|
L
 -87.4%
H
0.6
5.6
|
L
 -83.9%
H
0.6
15.8
|
L
 -99.4%
H
0.6
108.2
|
L
 -99.9%
H
0.6
899.5
|
L
 -99.7%
H
0.2
1310
|
| Protagonist Therapeutics Inc |
|
5,111.3
|
81.8
|
L
 -1.6%
H
80
83.7
|
L
 -2.0%
H
80
85.5
|
L
 -7.9%
H
78.8
89.1
|
L
 8.7%
H
74.8
96.5
|
L
 113.1%
H
33.7
96.5
|
L
 506.1%
H
12.8
96.5
|
L
 295.7%
H
6.9
96.5
|
L
H
4.5
96.5
|
| PureTech Health Plc ADR |
|
451.2
|
18.7
|
L
H
18.6
19.3
|
L
 2.9%
H
17.3
19.3
|
L
 11.7%
H
16.6
19.9
|
L
 5.2%
H
15.5
19.9
|
L
 -0.2%
H
13.3
20
|
L
 -42.6%
H
13.3
35.1
|
L
 -65.4%
H
13.3
65.9
|
L
H
13.3
65.9
|
| Quince Therapeutics Inc |
|
177.1
|
3.2
|
L
 -3.9%
H
3.2
3.4
|
L
 -7.0%
H
2.9
3.5
|
L
 -10.7%
H
2.6
3.7
|
L
 77.7%
H
1.4
4.6
|
L
 84.9%
H
0.7
4.6
|
L
 194.4%
H
0.5
4.6
|
L
 -92.0%
H
0.5
122.0
|
L
H
0.5
122.0
|
| uniQure NV |
|
1,434.0
|
23.0
|
L
 -5.5%
H
22.9
24.5
|
L
 2.8%
H
21.6
25.8
|
L
 -7.2%
H
21.2
28.8
|
L
 -66.1%
H
19.3
71.5
|
L
 45.7%
H
7.8
71.5
|
L
 8.4%
H
3.7
71.5
|
L
 -36.6%
H
3.7
71.5
|
L
 27.6%
H
3.7
82.5
|
| Rain Oncology Inc |
|
105.1
|
2.9
|
L
 -0.3%
H
2.8
3.0
|
L
 -10.3%
H
2.6
3.6
|
L
 -56.1%
H
2.6
8.4
|
L
 -50.3%
H
2.6
8.5
|
L
 138.8%
H
1.4
9.2
|
L
 -71.2%
H
0.8
11.3
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
130.7
|
1.3
|
L
 -2.9%
H
1.3
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 -4.3%
H
1.3
1.5
|
L
 -24.7%
H
1.3
2.6
|
L
 -6.3%
H
0.4
3.9
|
L
 -76.5%
H
0.4
8.8
|
L
 -99.4%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
387.4
|
3.6
|
L
 -1.9%
H
3.5
3.7
|
L
 -1.7%
H
3.5
4.0
|
L
 2.9%
H
3.4
4.1
|
L
 -9.1%
H
2.8
4.1
|
L
 -66.6%
H
2.2
11.5
|
L
 -83.9%
H
2.2
32.5
|
L
 -93.1%
H
2.2
67.5
|
L
 -88.6%
H
2.2
67.5
|
| Replimune Grp Inc |
|
577.3
|
7.4
|
L
 -2.3%
H
7.3
7.6
|
L
 5.0%
H
6.9
7.9
|
L
 -26.1%
H
6.8
10.1
|
L
 -21.1%
H
6.8
11.3
|
L
 -46.2%
H
2.7
14.8
|
L
 -71.6%
H
2.7
29.5
|
L
 -81.3%
H
2.7
45.6
|
L
H
2.7
54.9
|
| Revelation Biosciences Inc |
|
3.1
|
2.1
|
L
H
1.9
2.3
|
L
 -44.1%
H
1.9
5.8
|
L
 -39.2%
H
1.9
5.8
|
L
 -59.5%
H
1.9
5.8
|
L
 -95.4%
H
1.9
56.4
|
L
 -100.0%
H
1.9
65620.8
|
L
 -100.0%
H
1.9
2276064
|
L
H
1.9
2276064
|
| Relay Therapeutics Inc |
|
1,325.9
|
7.7
|
L
 -10%
H
7.6
8.5
|
L
 3.2%
H
7.4
8.6
|
L
 -10.6%
H
7.0
8.7
|
L
 3.7%
H
6.0
9.0
|
L
 62.1%
H
1.8
9.0
|
L
 -65.0%
H
1.8
23.2
|
L
 -86.2%
H
1.8
56.0
|
L
H
1.8
64.4
|
| Avidity Biosciences Inc |
|
10,918.0
|
72.5
|
L
 -0.3%
H
72.4
72.6
|
L
 0.0%
H
72.4
72.7
|
L
 0.5%
H
72
72.7
|
L
 3.5%
H
69.5
72.7
|
L
 138.0%
H
21.5
72.7
|
L
 208.7%
H
4.8
72.7
|
L
 200.4%
H
4.8
72.7
|
L
H
4.8
72.7
|
| TransCode Therapeutics Inc |
|
10.2
|
11.1
|
L
 -5.1%
H
10.4
11.4
|
L
 26.8%
H
8.7
12.6
|
L
 59.2%
H
6.1
12.6
|
L
 -15.7%
H
6.1
13.2
|
L
 -94.2%
H
6.1
468.4
|
L
 -100.0%
H
6.1
790944
|
L
H
6.1
5174400
|
L
H
6.1
5174400
|
| Recursion Pharma Inc (Class A) |
|
2,326.4
|
4.5
|
L
 -2.8%
H
4.4
4.6
|
L
 1.6%
H
4.4
5.2
|
L
 5.2%
H
4.1
5.2
|
L
 -29.1%
H
3.8
6.3
|
L
 -36.4%
H
3.8
12.4
|
L
 -47.7%
H
3.8
16.7
|
L
H
3.8
42.8
|
L
H
3.8
42.8
|
| Rhythm Pharma Inc |
|
6,851.8
|
102.7
|
L
 -2.7%
H
101.2
106.0
|
L
 0.1%
H
101.2
109.0
|
L
 -6.7%
H
96.2
114.2
|
L
 -8.0%
H
95.3
122.2
|
L
 81.7%
H
45.9
122.2
|
L
 253.1%
H
15.5
122.2
|
L
 230.0%
H
3.0
122.2
|
L
H
3.0
122.2
|
| SAB Biotherapeutics Inc |
|
209.9
|
4.4
|
L
 3.0%
H
4.4
4.7
|
L
 10.0%
H
3.9
4.7
|
L
 16.7%
H
3.4
4.7
|
L
 45.5%
H
2.8
4.7
|
L
 1.2%
H
1
6.6
|
L
 558.2%
H
0.4
6.6
|
L
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
1,265.2
|
4.8
|
L
 -4.4%
H
4.7
5.0
|
L
 3.7%
H
4.6
5.2
|
L
 7.7%
H
3.9
5.2
|
L
 -9.5%
H
3.2
5.6
|
L
 41.0%
H
1.3
6.6
|
L
 -1.2%
H
1.3
12
|
L
H
1.3
44.6
|
L
H
1.3
44.6
|
| Cassava Sciences Inc |
|
98.5
|
2.0
|
L
 -3.8%
H
2.0
2.2
|
L
 2.5%
H
2
2.3
|
L
 -6.4%
H
2.0
2.3
|
L
 -46.3%
H
2.0
3.8
|
L
 -17.4%
H
1.2
5.0
|
L
 -92.9%
H
1.2
42.2
|
L
 -89.7%
H
1.2
146.2
|
L
 -82.4%
H
0.8
146.2
|
| Seer Inc (Class A) |
|
105.2
|
1.9
|
L
 -2.1%
H
1.9
1.9
|
L
 0.5%
H
1.9
2.0
|
L
 1.6%
H
1.8
2.0
|
L
 -21.1%
H
1.8
2.4
|
L
 -21.8%
H
1.6
2.4
|
L
 -63.1%
H
1.5
6.2
|
L
 -97.3%
H
1.5
71.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,127.3
|
7.3
|
L
 -1.6%
H
7.2
7.8
|
L
 0.7%
H
7.2
7.9
|
L
 9.0%
H
6.4
8.3
|
L
 -17.7%
H
6.0
9.2
|
L
 -29.0%
H
6.0
15.6
|
L
 -29.0%
H
6.0
15.6
|
L
 -29.0%
H
6.0
15.6
|
L
 -29.0%
H
6.0
15.6
|
| Sangamo Therapeutics Inc |
|
121.1
|
0.4
|
L
 -5.3%
H
0.4
0.4
|
L
 -2.7%
H
0.4
0.4
|
L
 -14.3%
H
0.4
0.5
|
L
 -42.9%
H
0.4
0.6
|
L
 -68.1%
H
0.4
1.4
|
L
 -89.9%
H
0.3
3.7
|
L
 -97.4%
H
0.3
15.5
|
L
 -94.5%
H
0.3
27.5
|
| Solid Biosciences Inc |
|
510.3
|
6.6
|
L
 -0.3%
H
6.4
6.7
|
L
 16.6%
H
5.6
7.0
|
L
 12.2%
H
4.9
7.0
|
L
 11.0%
H
3.8
7.0
|
L
 108.6%
H
2.4
7.4
|
L
 -14.3%
H
1.8
15.1
|
L
 -93.0%
H
1.8
173.7
|
L
H
1.8
822.6
|
| Summit Therapeutics Inc |
|
11,643.1
|
15.6
|
L
 -1.6%
H
15.5
15.9
|
L
 -2.6%
H
15.5
18.0
|
L
 -13.8%
H
15.5
20.2
|
L
 -19.6%
H
15.5
20.2
|
L
 -33.5%
H
15.5
36.9
|
L
 384.2%
H
1.3
36.9
|
L
 113.1%
H
0.7
36.9
|
L
 89.6%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,786.1
|
20.6
|
L
 -3.6%
H
20.5
21.4
|
L
 1.6%
H
19.8
22.2
|
L
 -3.5%
H
19.6
22.4
|
L
 56.8%
H
13.0
22.7
|
L
 43.9%
H
8.6
22.7
|
L
 -27.0%
H
8.6
29.9
|
L
 6.6%
H
8.6
29.9
|
L
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
12.7
|
10.1
|
L
 1.4%
H
9.6
10.3
|
L
 4.9%
H
9.3
11.5
|
L
 12%
H
8.4
12
|
L
 -0.4%
H
7.5
13.3
|
L
 5%
H
5
18.4
|
L
 -66.6%
H
5
38.8
|
L
H
5
530
|
L
H
5
530
|
| Senti Biosciences Inc |
|
27.1
|
1.0
|
L
 -2.8%
H
1.0
1.1
|
L
 -3.7%
H
1.0
1.2
|
L
 -2.8%
H
1.0
1.2
|
L
 -54.0%
H
1.0
2.9
|
L
 -77.2%
H
1.0
5.1
|
L
 -94.2%
H
1.0
20.2
|
L
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
87.7
|
81.9
|
L
 -2.8%
H
81.1
86
|
L
 14.6%
H
72.6
87.4
|
L
 -4.5%
H
71.5
91.1
|
L
 -33.4%
H
71.3
131.5
|
L
 192.7%
H
4.3
240
|
L
 -62.7%
H
4.3
446.3
|
L
 -94.8%
H
4.3
2136.8
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
125.6
|
2.2
|
L
 -5.9%
H
2.2
2.4
|
L
 -6.3%
H
2.2
2.5
|
L
 -3.9%
H
2.2
2.7
|
L
 -2.6%
H
2.2
2.8
|
L
 159.3%
H
0.5
3.2
|
L
 22.5%
H
0.5
3.2
|
L
 -87.6%
H
0.5
22.2
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
4,399.6
|
43.1
|
L
 -2.0%
H
42.9
44.6
|
L
 -3.6%
H
42.9
48.3
|
L
 -5.6%
H
40.6
48.3
|
L
 41.4%
H
27.1
48.3
|
L
 1.4%
H
22.7
48.3
|
L
 240.7%
H
5.6
48.3
|
L
 -24.1%
H
4.3
70
|
L
H
4.3
70
|
| Surrozen Inc |
|
185.8
|
21.7
|
L
 -5.9%
H
21.2
23.2
|
L
 20.6%
H
18.7
24.1
|
L
 -2.3%
H
16.8
24.1
|
L
 55.6%
H
11.4
24.9
|
L
 93.2%
H
5.9
24.9
|
L
 2911.1%
H
0.3
24.9
|
L
H
0.3
24.9
|
L
H
0.3
24.9
|
| Stoke Therapeutics Inc |
|
1,679.2
|
29.4
|
L
 -0.4%
H
29.1
30.1
|
L
 2.4%
H
28.5
31.0
|
L
 -7.9%
H
25.2
37.3
|
L
 -10.9%
H
20.3
37.3
|
L
 178.2%
H
5.4
38.7
|
L
 205.3%
H
3.4
38.7
|
L
 -50.8%
H
3.4
68
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
263.9
|
4.2
|
L
 3.7%
H
4.1
4.5
|
L
 -3.9%
H
3.9
4.7
|
L
 24.5%
H
3.2
4.9
|
L
 102.4%
H
1.7
4.9
|
L
 265.8%
H
0.7
4.9
|
L
 12.4%
H
0.7
11.8
|
L
 -91.0%
H
0.7
59.6
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
6.7
|
5.2
|
L
 7.9%
H
4.5
5.3
|
L
 158.7%
H
1.9
8.6
|
L
 87.1%
H
1.4
8.6
|
L
 -12.2%
H
1.4
8.6
|
L
 -70.0%
H
1.4
24
|
L
H
1.4
2076
|
L
H
1.4
2076
|
L
H
1.4
2076
|
| Alaunos Therapeutics Inc |
|
6.2
|
2.8
|
L
 -5.8%
H
2.8
2.9
|
L
 -4.5%
H
2.8
3.1
|
L
 -13.9%
H
2.6
4.0
|
L
 -3.8%
H
2.3
4.5
|
L
 54.4%
H
1.3
6.2
|
L
 280.8%
H
0.0
6.2
|
L
 -34.4%
H
0.0
6.2
|
L
 -45.9%
H
0.0
9.7
|
| Tscan Therapeutics Inc |
|
60.2
|
1.1
|
L
 -5.4%
H
1.1
1.1
|
L
 -5.4%
H
1.1
1.2
|
L
H
1.0
1.3
|
L
 -53.5%
H
0.9
2.3
|
L
 -56.7%
H
0.9
2.7
|
L
 -40.8%
H
0.9
9.7
|
L
H
0.9
14.7
|
L
H
0.9
14.7
|
| Bio-Techne |
|
10,215.1
|
65.6
|
L
 -3.9%
H
65.2
68.0
|
L
 -5.8%
H
65.2
72.2
|
L
 10.7%
H
58.4
72.2
|
L
 2.0%
H
54.2
72.2
|
L
 -14.2%
H
46.0
79.3
|
L
 -19.3%
H
46.0
89.9
|
L
 -17.6%
H
46.0
136.0
|
L
 214.7%
H
20.1
136.0
|
| Terns Pharma Inc |
|
3,726.4
|
34.3
|
L
 -2.4%
H
34.1
35.4
|
L
 -6.3%
H
33.6
37.9
|
L
 -17.5%
H
33.4
41.8
|
L
 325.1%
H
7.8
48.3
|
L
 656.3%
H
1.9
48.3
|
L
 333.1%
H
1.9
48.3
|
L
H
1.5
48.3
|
L
H
1.5
48.3
|
| Instil Bio Inc |
|
48.1
|
7.1
|
L
 -1.0%
H
7
7.2
|
L
 0.1%
H
6.8
7.3
|
L
 -37.3%
H
5.7
12.9
|
L
 -64.3%
H
5.7
19.9
|
L
 -70.8%
H
5.7
42.8
|
L
 764.6%
H
0.3
92
|
L
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
1,505.7
|
11.2
|
L
 -5.7%
H
11.1
12.2
|
L
 -10.6%
H
11.1
12.8
|
L
 29.0%
H
8.5
13.5
|
L
 43.9%
H
7.4
13.5
|
L
 265.4%
H
1.0
13.5
|
L
 71.2%
H
1.0
13.5
|
L
H
1.0
18.8
|
L
H
1.0
18.8
|
| Entrada Therapeutics Inc |
|
426.1
|
11.2
|
L
 1.4%
H
10.5
11.3
|
L
 5.0%
H
10.5
12.2
|
L
 7.1%
H
9.3
12.2
|
L
 52.5%
H
6.1
12.2
|
L
 -15.4%
H
4.9
14.3
|
L
 -7.5%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
1,347.7
|
10.5
|
L
 -4.1%
H
10.2
11.1
|
L
 0.9%
H
9.9
11.2
|
L
 -18.2%
H
9.9
13.2
|
L
 0.1%
H
9.9
14.4
|
L
 164.7%
H
3.8
14.4
|
L
 327.2%
H
1.0
14.4
|
L
 258.7%
H
0.5
14.4
|
L
H
0.5
14.4
|
| Taysha Gene Therapies Inc |
|
1,227.2
|
4.5
|
L
 -5.9%
H
4.4
4.8
|
L
 -3.5%
H
4.4
5.1
|
L
 -23.2%
H
4.4
5.8
|
L
 -8.2%
H
3.7
6.0
|
L
 192.8%
H
1.1
6.0
|
L
 154.5%
H
0.5
6.0
|
L
 -85.1%
H
0.5
31.6
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
2,574.1
|
42.0
|
L
 -1.4%
H
40.7
43.2
|
L
 0.9%
H
40.7
45.8
|
L
 27.1%
H
31
45.8
|
L
 22.9%
H
23.3
45.8
|
L
 -19.6%
H
23.3
54.7
|
L
 44.1%
H
11.5
60.9
|
L
 -73.7%
H
11.5
202.2
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
2,667.7
|
21.1
|
L
 -2.5%
H
21
21.6
|
L
 -4.4%
H
21
23.6
|
L
 27.8%
H
15.9
23.6
|
L
 55.1%
H
12.3
23.6
|
L
 42.0%
H
6.8
23.6
|
L
 -56.7%
H
6.8
63.6
|
L
 -87.1%
H
6.8
209.0
|
L
H
6.8
209.0
|
| UroGen Pharma Ltd |
|
998.0
|
21.3
|
L
 -2.4%
H
21.0
22.1
|
L
 10.3%
H
18.1
22.1
|
L
 -7.4%
H
18.1
24.1
|
L
 2.3%
H
18.1
30
|
L
 103.4%
H
3.4
30
|
L
 128.0%
H
3.4
30
|
L
 -5.8%
H
3.4
30
|
L
H
3.4
69.6
|
| Vera Therapeutics Inc (Class A) |
|
3,202.2
|
45.1
|
L
 -3.5%
H
43.9
47.1
|
L
 0.6%
H
43.9
49.3
|
L
 -15.8%
H
43.9
53.8
|
L
 48.3%
H
23.1
56.1
|
L
 29.5%
H
18.5
56.1
|
L
 416.1%
H
6.0
56.1
|
L
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,053.2
|
7.6
|
L
 -1.6%
H
7.4
7.8
|
L
 26.2%
H
6.0
7.8
|
L
 26.2%
H
5.6
7.8
|
L
 22.3%
H
4.8
7.8
|
L
 -26.4%
H
4.2
11
|
L
 -75.5%
H
4.2
31.0
|
L
 -90.9%
H
4.2
83.5
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
532.0
|
13.7
|
L
 -6.9%
H
13.7
14.8
|
L
 -21.9%
H
13.7
18.6
|
L
 -6.7%
H
10.3
18.6
|
L
 -51.2%
H
6.5
28.7
|
L
 888.5%
H
0.1
50.0
|
L
 165.3%
H
0.1
50.0
|
L
H
0.1
63.6
|
L
H
0.1
63.6
|
| Verastem Inc |
|
469.2
|
6.2
|
L
 -4.2%
H
6.1
6.5
|
L
 -6.3%
H
6.1
6.8
|
L
 -22.7%
H
6.1
8.9
|
L
 -28.6%
H
6.1
10.8
|
L
 9.5%
H
4.0
11.2
|
L
 -21.8%
H
2.1
15.2
|
L
 -72.8%
H
2.1
59.2
|
L
 -61.0%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
23.3
|
0.6
|
L
 -3.3%
H
0.6
0.6
|
L
 -7.8%
H
0.6
0.7
|
L
 -19.2%
H
0.6
0.8
|
L
 -84.9%
H
0.6
5.1
|
L
 -79.5%
H
0.6
5.1
|
L
 -90.7%
H
0.6
24.7
|
L
 -99.1%
H
0.6
106.5
|
L
 -99.8%
H
0.6
270
|
| Ventyx Biosciences Inc |
|
1,002.3
|
14.0
|
L
 -0.1%
H
13.9
14
|
L
 0.7%
H
13.9
14.1
|
L
 50.9%
H
7.1
25
|
L
 116.9%
H
6.4
25
|
L
 581.5%
H
0.8
25
|
L
 -66.3%
H
0.8
47.3
|
L
H
0.8
47.3
|
L
H
0.8
47.3
|
| Voyager Therapeutics Inc |
|
220.7
|
4.0
|
L
 0.8%
H
3.9
4.1
|
L
 8.2%
H
3.6
4.2
|
L
 -2.7%
H
3.6
4.2
|
L
 -17.5%
H
3.6
4.8
|
L
 -29.5%
H
2.6
5.8
|
L
 -55.9%
H
2.6
14.3
|
L
 -48.6%
H
2.5
14.3
|
L
 -64.0%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
816.8
|
9.4
|
L
 -2.1%
H
9.3
9.7
|
L
 -3.6%
H
9.2
10.3
|
L
 12.0%
H
8.1
10.4
|
L
 1.7%
H
8.0
10.4
|
L
 94.2%
H
4.8
12.3
|
L
 -32.9%
H
3.6
17.1
|
L
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
2,364.7
|
12.7
|
L
 -4.7%
H
12.6
13.5
|
L
 -7.9%
H
12.6
14.5
|
L
 -28.4%
H
12.6
19.5
|
L
 67.1%
H
6.5
21.7
|
L
 4.3%
H
5.3
21.7
|
L
 195.4%
H
3.2
21.7
|
L
 26.8%
H
1.2
21.7
|
L
 -3.7%
H
1.2
56
|
| XBiotech Inc |
|
80.5
|
2.6
|
L
 -2.6%
H
2.6
2.7
|
L
 4.4%
H
2.5
2.7
|
L
 6.9%
H
2.3
2.7
|
L
 2.7%
H
2.1
3.4
|
L
 -27.5%
H
2.1
3.7
|
L
 -40.5%
H
2.1
10.0
|
L
 -85.4%
H
2.1
20.8
|
L
 -66.2%
H
2.1
26.4
|
| Exicure Inc |
|
26.7
|
4.2
|
L
 -5.8%
H
4.2
4.6
|
L
 -31.8%
H
4.2
6.6
|
L
 -30.1%
H
4.2
6.6
|
L
 -10.5%
H
3.5
9.5
|
L
 -64.3%
H
3.1
15.9
|
L
 -40.1%
H
0.3
36
|
L
 -98.7%
H
0.3
424.5
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
1,188.0
|
7.2
|
L
 -4.7%
H
7.1
7.5
|
L
 -5.9%
H
7.1
7.9
|
L
 -2.9%
H
6.9
8.4
|
L
 -23.1%
H
6.5
10.1
|
L
 106.3%
H
3.4
10.1
|
L
 468.3%
H
1.1
10.1
|
L
 33.3%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
316.5
|
3.6
|
L
 -2.2%
H
3.6
3.7
|
L
 -1.4%
H
3.6
3.9
|
L
 -19.6%
H
3.6
4.4
|
L
 -3.2%
H
3.1
4.6
|
L
 638.8%
H
0.2
6.6
|
L
 244.8%
H
0.2
6.6
|
L
 -52.6%
H
0.2
10.7
|
L
H
0.2
172.2
|
| Xencor Inc |
|
881.9
|
12.4
|
L
 -6.2%
H
12.3
13.4
|
L
 -2.3%
H
12.3
13.7
|
L
 -18.9%
H
12.3
15.4
|
L
 -13.5%
H
12.3
18.7
|
L
 -35.8%
H
6.9
19.5
|
L
 -62%
H
6.9
38.2
|
L
 -73.8%
H
6.9
58.3
|
L
 6.7%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
4.4
|
8.6
|
L
 -6.2%
H
8.4
9.2
|
L
 -29.2%
H
8.4
13.2
|
L
 -34.2%
H
8.4
14.9
|
L
 -62.2%
H
8.4
27
|
L
 -99.5%
H
8.4
1690.5
|
L
 -100.0%
H
8.4
12966480
|
L
 -100.0%
H
8.4
67850460
|
L
 -100.0%
H
8.4
67850460
|
| Zentalis Pharma Inc |
|
165.8
|
2.6
|
L
 -12.6%
H
2.6
3
|
L
 -10.8%
H
2.6
3.3
|
L
 88.2%
H
1.3
4.0
|
L
 48.8%
H
1.2
4.0
|
L
 6.7%
H
1.0
4.0
|
L
 -89.1%
H
1.0
31.5
|
L
 -93.5%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
388.8
|
6.0
|
L
 -7%
H
6.0
6.5
|
L
 19.4%
H
4.9
6.6
|
L
 28.6%
H
4.4
6.6
|
L
 52.2%
H
3.3
6.6
|
L
 260.2%
H
1.0
6.6
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
1,905.5
|
17.2
|
L
 0.9%
H
17.2
17.8
|
L
 -9.0%
H
17.0
19
|
L
 -6.2%
H
17.0
19.8
|
L
 -34.7%
H
16.8
27.3
|
L
 -35.9%
H
16.8
44.3
|
L
 -61.7%
H
13.5
44.5
|
L
 -89.0%
H
13.5
187.5
|
L
H
13.5
193.5
|
| Apogee Therapeutics Inc |
|
4,829.6
|
70.7
|
L
 -2.3%
H
69.6
73.5
|
L
 -13.8%
H
68.0
82
|
L
 -8.6%
H
68.0
84.6
|
L
 25.7%
H
52.3
84.6
|
L
 75.8%
H
26.2
84.6
|
L
H
14.2
84.6
|
L
H
14.2
84.6
|
L
H
14.2
84.6
|
| Intensity Therapeutics Inc |
|
22.8
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 -5%
H
0.4
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 58.3%
H
0.2
1.7
|
L
 -83.6%
H
0.2
2.6
|
L
 -90.5%
H
0.2
11.4
|
L
 -90.5%
H
0.2
11.4
|
L
 -90.5%
H
0.2
11.4
|
| Renovaro Biosciences Inc |
|
18.7
|
0.8
|
L
 -4.8%
H
0.8
0.9
|
L
 -8.1%
H
0.8
1.0
|
L
 -17.5%
H
0.8
1.0
|
L
 -23.8%
H
0.8
1.7
|
L
 -90.3%
H
0.8
14
|
L
H
0.8
52.5
|
L
H
0.8
52.5
|
L
H
0.8
52.5
|
| Elutia Inc (Class A) |
|
44.8
|
1.1
|
L
 5%
H
0.9
1.1
|
L
 25%
H
0.8
1.1
|
L
 94.4%
H
0.5
1.1
|
L
 16.7%
H
0.5
1.1
|
L
 -64.4%
H
0.5
3.5
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Tharimmune Inc |
|
160.1
|
4.1
|
L
 12.8%
H
3.6
4.2
|
L
 38.7%
H
2.7
4.2
|
L
 56.4%
H
2.6
4.2
|
L
 31.1%
H
2.2
6.9
|
L
 101.5%
H
1.0
9.1
|
L
 -98.2%
H
0.3
993.8
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Gyre Therapeutics Inc |
|
773.6
|
8.0
|
L
 -0.7%
H
8.0
8.2
|
L
 1.3%
H
7.7
8.4
|
L
 10.6%
H
6.8
8.4
|
L
 0.1%
H
6.8
8.5
|
L
 -29.4%
H
6.1
13.7
|
L
 7.1%
H
5.6
130.5
|
L
 7.1%
H
5.6
130.5
|
L
 7.1%
H
5.6
130.5
|
| Lexeo Therapeutics Inc |
|
543.0
|
7.4
|
L
 -1.3%
H
7.3
7.7
|
L
 2.5%
H
7.1
7.8
|
L
 -27.4%
H
6.9
10.8
|
L
 -24.4%
H
6.9
11.0
|
L
 26.8%
H
1.5
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Korro Bio Inc |
|
110.1
|
11.7
|
L
 8.9%
H
11.0
12.4
|
L
 36.3%
H
8.5
12.4
|
L
 44.0%
H
7.7
12.4
|
L
 -70.5%
H
5.2
42.7
|
L
 -68.3%
H
5.2
55.9
|
L
H
5.2
98
|
L
H
5.2
98
|
L
H
5.2
98
|
| Cartesian Therapeutics Inc |
|
189.3
|
7.3
|
L
 -1.6%
H
7.2
7.8
|
L
 0.7%
H
7.2
7.9
|
L
 9.0%
H
6.4
8.3
|
L
 -17.7%
H
6.0
9.2
|
L
 -62.5%
H
6.0
20
|
L
 -99.5%
H
6.0
1791
|
L
 -99.8%
H
6.0
5130
|
L
H
6.0
25199.6
|
| Elevai Labs Inc |
|
4.0
|
3.4
|
L
 -0.6%
H
3.4
3.6
|
L
 4.9%
H
3.1
3.8
|
L
 119.4%
H
1.3
9.6
|
L
 -42.9%
H
1.3
9.6
|
L
 -93.2%
H
1.3
49.9
|
L
H
1.3
20796.6
|
L
H
1.3
20796.6
|
L
H
1.3
20796.6
|
| Spyre Therapeutics Inc |
|
2,571.4
|
33.1
|
L
 -0.7%
H
32.5
34.0
|
L
 -1.8%
H
31.5
35.1
|
L
 0.6%
H
28
35.1
|
L
 34.9%
H
21.1
35.3
|
L
 59.2%
H
10.9
35.3
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
| Neurogene Inc |
|
298.5
|
19.3
|
L
 -3.0%
H
19.0
20.4
|
L
 10.0%
H
17.5
20.4
|
L
 -3.7%
H
16.5
23.0
|
L
 -39.9%
H
16.5
35.5
|
L
 27.8%
H
6.9
37.3
|
L
 35.9%
H
6.9
74.5
|
L
 35.9%
H
6.9
74.5
|
L
 35.9%
H
6.9
74.5
|
| Cg Oncology Inc |
|
4,448.5
|
53.8
|
L
 -2.3%
H
53.5
55.8
|
L
 -1.6%
H
51.9
57.9
|
L
 35.1%
H
39.1
57.9
|
L
 21.6%
H
35.8
57.9
|
L
 76.5%
H
14.8
57.9
|
L
H
14.8
57.9
|
L
H
14.8
57.9
|
L
H
14.8
57.9
|
| FibroBiologics Inc |
|
23.9
|
0.4
|
L
 -2.7%
H
0.4
0.4
|
L
 12.5%
H
0.3
0.4
|
L
 44%
H
0.2
0.4
|
L
 -16.3%
H
0.2
0.4
|
L
 -77.1%
H
0.2
2
|
L
H
0.2
55
|
L
H
0.2
55
|
L
H
0.2
55
|
| Kyverna Therapeutics Inc |
|
499.5
|
8.4
|
L
 -9.7%
H
8.2
9.4
|
L
 -7.1%
H
8.2
10.6
|
L
 -10.9%
H
7.8
10.6
|
L
 7.3%
H
6.2
13.7
|
L
 133.4%
H
1.8
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
60.1
|
1.6
|
L
 -3.6%
H
1.6
1.7
|
L
 -0.6%
H
1.6
1.8
|
L
 -5.9%
H
1.6
1.9
|
L
 -41.6%
H
1.5
2.8
|
L
 -42.2%
H
1.2
4.0
|
L
H
1.2
15
|
L
H
1.2
15
|
L
H
1.2
15
|
| Tevogen Bio Holdings Inc |
|
64.5
|
0.3
|
L
 -5.9%
H
0.3
0.4
|
L
H
0.3
0.4
|
L
 -15.8%
H
0.3
0.4
|
L
 -49.2%
H
0.3
0.7
|
L
 -81.0%
H
0.3
1.7
|
L
H
0.3
21.1
|
L
H
0.3
21.1
|
L
H
0.3
21.1
|
| NeOnc Tech Holdings Inc |
|
234.0
|
9.8
|
L
 6.9%
H
9.1
10.3
|
L
 16.8%
H
8.0
10.3
|
L
 13.9%
H
8.0
10.7
|
L
 18.5%
H
5.6
12
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
| LENZ Therapeutics Inc |
|
583.6
|
18.7
|
L
 -3.8%
H
18.5
19.8
|
L
 -3.8%
H
18.5
21.8
|
L
 10.6%
H
14.4
21.8
|
L
 -40.4%
H
14.4
32.1
|
L
 -24.4%
H
14.4
50.4
|
L
 -25.2%
H
14.4
50.4
|
L
 -25.2%
H
14.4
50.4
|
L
 -25.2%
H
14.4
50.4
|
| Boundless Bio Inc |
|
27.1
|
1.2
|
L
 -0.8%
H
1.2
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 0.8%
H
1.1
1.4
|
L
 -18.8%
H
1
1.5
|
L
 -48.5%
H
1
2.5
|
L
H
1
14.7
|
L
H
1
14.7
|
L
H
1
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
527.1
|
14.4
|
L
 2.4%
H
13.6
14.8
|
L
 21.8%
H
11.6
14.8
|
L
 16.3%
H
8.6
14.8
|
L
 28.7%
H
8.6
14.8
|
L
 33.9%
H
3.4
14.8
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
438.6
|
8.7
|
L
 -3.7%
H
8.6
9.0
|
L
 -4.0%
H
8.6
9.3
|
L
 14.7%
H
7.1
9.3
|
L
 56.6%
H
5.3
9.3
|
L
 175.8%
H
2.7
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
10.1
|
3
|
L
 -10.7%
H
3.0
3.4
|
L
 -8.5%
H
2.7
3.7
|
L
 0.7%
H
2.7
5.3
|
L
 -26.7%
H
1.9
5.3
|
L
 96.1%
H
1.0
5.8
|
L
 -64.0%
H
0.6
9.5
|
L
 -64.0%
H
0.6
9.5
|
L
 -64.0%
H
0.6
9.5
|
| Artiva Biotherapeutics Inc |
|
109.7
|
4.5
|
L
 -7.8%
H
4.5
4.9
|
L
 -3.3%
H
4.5
5.1
|
L
 6.9%
H
4.1
5.2
|
L
 -11.3%
H
3.0
7.3
|
L
 -24.9%
H
1.5
7.4
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
1,608.8
|
35.8
|
L
 -0.7%
H
35.1
37.2
|
L
 -16.9%
H
35.1
44.0
|
L
 16.0%
H
27.8
44.9
|
L
 105.5%
H
17.0
44.9
|
L
 244.9%
H
4.8
44.9
|
L
H
4.8
44.9
|
L
H
4.8
44.9
|
L
H
4.8
44.9
|
| BioAge Labs Inc |
|
814.6
|
19.5
|
L
 -0.5%
H
19.2
19.9
|
L
 -8.5%
H
18.2
21.5
|
L
 40.6%
H
11.9
24
|
L
 155.7%
H
6.8
24
|
L
 263.3%
H
2.9
24
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| OnKure Therapeutics Inc (Class A) |
|
38.3
|
2.8
|
L
 -0.7%
H
2.8
3.0
|
L
 -5.0%
H
2.7
3.2
|
L
 1.1%
H
2.7
3.4
|
L
 -20.7%
H
2.5
3.6
|
L
 -45.5%
H
1.7
6.5
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
4
|
L
 4.4%
H
3.7
4.1
|
L
 -9.9%
H
3.3
5.5
|
L
 -32.9%
H
3.3
6.6
|
L
 2.6%
H
2.9
7.3
|
L
 73.9%
H
1.3
7.3
|
L
 73.9%
H
1.3
7.3
|
L
 73.9%
H
1.3
7.3
|
L
 73.9%
H
1.3
7.3
|
| Upstream Bio Inc |
|
1,644.4
|
30.4
|
L
 -6.4%
H
30.0
32.5
|
L
 -1.8%
H
29.8
32.8
|
L
 3.2%
H
25
33.7
|
L
 29.1%
H
22.0
33.7
|
L
 206.8%
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Medicus Pharma Ltd |
|
29.2
|
1.2
|
L
 -2.5%
H
1.2
1.2
|
L
 -13.9%
H
1.1
1.5
|
L
 -24.4%
H
1.1
1.7
|
L
 -50.6%
H
1.1
2.6
|
L
 -82.5%
H
1.1
8.9
|
L
 -82.5%
H
1.1
8.9
|
L
 -82.5%
H
1.1
8.9
|
L
 -82.5%
H
1.1
8.9
|
| Telix Pharma Ltd (ADR) |
|
2,711.3
|
8.1
|
L
 -3.1%
H
8.1
8.5
|
L
 4.8%
H
7.2
8.5
|
L
 0.9%
H
7.2
8.5
|
L
 -26.0%
H
7.2
10.9
|
L
 -55.0%
H
7.2
30.4
|
L
H
7.2
30.4
|
L
H
7.2
30.4
|
L
H
7.2
30.4
|
| Palvella Therapeutics Inc |
|
931.7
|
78.7
|
L
 -6.3%
H
78.4
85.0
|
L
 -19.7%
H
78.4
98.0
|
L
 -23.9%
H
78.4
106.3
|
L
 11.8%
H
69.0
114.7
|
L
 510.2%
H
12.5
114.7
|
L
 478.8%
H
11.2
114.7
|
L
 478.8%
H
11.2
114.7
|
L
 478.8%
H
11.2
114.7
|
| Sionna Therapeutics Inc |
|
1,880.2
|
42.1
|
L
 -2.9%
H
42.0
44.2
|
L
 5.3%
H
39.1
44.2
|
L
 -3.6%
H
34.6
45
|
L
 9.9%
H
32.4
45
|
L
H
7.3
45
|
L
H
7.3
45
|
L
H
7.3
45
|
L
H
7.3
45
|
| Zenas Biopharma Inc |
|
1,152.5
|
21.5
|
L
 7.0%
H
19.3
21.6
|
L
 2.8%
H
19
21.6
|
L
 -49.5%
H
13.5
42.7
|
L
 -32.5%
H
13.5
44.6
|
L
 105.1%
H
8.9
44.6
|
L
 105.1%
H
8.9
44.6
|
L
 105.1%
H
8.9
44.6
|
L
 105.1%
H
8.9
44.6
|
| Propanc Biopharma Inc |
|
5.2
|
0.4
|
L
 30%
H
0.3
0.4
|
L
 30%
H
0.2
0.4
|
L
 -33.9%
H
0.2
0.6
|
L
 -73.7%
H
0.2
1.5
|
L
 -86.4%
H
0.2
9.4
|
L
 -86.4%
H
0.2
9.4
|
L
 -86.4%
H
0.2
9.4
|
L
 -86.4%
H
0.2
9.4
|